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A guide to this thesis
The first publications of the clinical manifestations of Lyme borreliosis in Dutch
literature date from 1984 (1-3). Wokke er a/., described ten Dutch patients with
lymphocytic meningoradiculitis (Bannwarth's syndrome). The authors already
discussed similarities between this syndrome and Lyme disease in the USA (3).
The first cases of Lyme arthritis in the Netherlands were described by van
den Hoogen ef a/ (4). At about the same time we observed a patient with arthritis
of his first metatarsal joint as part of a typical presentation of Lyme borreliosis
(2). These observations led us to study the prevalence, incidence and clinical
manifestations of Lyme arthritis in the Netherlands.
Chapter 1 provides an overview of Lyme borreliosis, and a survey among all
Dutch rheumatologists regarding the prevalence of Lyme arthritis is reported in
Chapter 2. This survey yielded 42 patients with Lyme arthritis. This assessment
of the Burden of Illness fits in with step one of the Technology Assessment
Iterative Loop (figure 1) (5,6). This chapter includes the clinical signs and
symptoms, serological findings and the distribution of HLA DR alleles of these
patients. Several of these patients had arthritis but no other clinical features of
Lyme borreliosis, and positive antibodies to flo/re/ia bHrgrfor/m (fi. öwrg-
rfor/en). Therefore, we hypothesized that unrecognized cases of Lyme arthritis
might be present among patients with arthritis of undetermined etiology (Chap-
ter 3). This paper describes the results of a study of 73 patients with arthritis of
undetermined etiology for clinical manifestations suggestive of Lyme borrelio-
sis. These patients were studied together with healthy controls and patients with
classified arthritis (step number three of the Technology Assessment Iterative
Loop).
In 1989, Weyand suggested that the spirochete £. frurgcfor/m might trigger
reactive arthritis in a genetically susceptible HLA B27 positive host (7). This
finding would have therapeutic implications and raised challenging new ques-
tions about pathogenetic mechanisms underlying the spondylarthropathies (8).
Ankylosing spondylitis is the prototype of this group of disorders to which
reactive arthritis belongs. Indeed, we also found positive antibodies to iB.
/en more often among Swiss ankylosing spondylitis patients than
1 - BURDEN OF ILLNESS
potential for reducing
"modifiable" burden of illness
\
7 - MONITORING AND
REASSESSMENT 2 - EFFICACY
selection and application of therapeutic potential in ideal
indicators of success and circumstances
reassessment of burden of illness
6 - SYNTHESIS AND 3 - SCREENING AND
IMPLEMENTATION DIAGNOSIS
integration of feasibility, effect, accurate identification of those
and efficiency in need of treatment
5 - EFFICIENCY 4 - COMMUNITY
relationships between costs « EFFECTIVENESS
and effects including clinical performance
and compliance by patients and
providers
Figure 1. The Technology Assessment Iterative Loop applied to the studies in the thesis:
"Lyme Arthritis in the Netherlands, A Clinical and Epidemiological Study"
among their HLA B27 positive relatives (9). Chapter 4 is a study of the
relationship between fl. ÖMrgdor/èn and seronegative spondylarthropathies in
125 Dutch patients with ankylosing spondylitis.
From a study by Fahrer er a/, among Swiss orienteers, it became clear that
positive serology is quite common, but that the clinical disease itself occurs
infrequently (10). We were able to perform a similar study in a Dutch population
at risk for Lyme borreliosis (Chapter 5). In the same study, we assessed the
clinical usefulness of several diagnostic tools by calculating likelihood ratios for
(1) the recognition of erythema migrans, (2) a history of tick bites, and (3)
positive Lyme serology.
In Chapter 6, we analyzed clinical data of 102 patients with arthritis of
undetermined etiology to improve the appropriateness and efficiency of diag-
nostic serologic tests and subsequent antibiotic treatment. Likelihood ratios for
different cut off levels in the clinical history of patients with arthritis of undeter-
mined etiology were calculated and applied.
A brief overview how to prevent Lyme borreliosis and especially Lyme
arthritis is given in Chapter 7. Regarding the latter, we conclude that recogni-
tion of erythema migrans in particular and the other early stages of Lyme
borreliosis is of paramount importance in preventing Lyme arthritis.
Chapters 4 to 7 deal mainly with step number three of the Technology
Assessment Iterative Loop. This step deals with accurate identification of those
in need of treatment.
Evaluating knowledge of general practitioners about rheumatology, we were
able to assess recognition and knowledge of Lyme borreliosis. We presented two
cases of Lyme borreliosis and two photographs of erythema migrans to general
practitioners, rheumatologists and dermatologists. The results of this edu-
cational study are presented in Chapter 8, which fits into step number four of
the Technology Assessment Iterative Loop. Indeed, given an effective treat-
ment, community effectiveness depends a great deal on clinical performance.
Chapter 9 gives a general discussion. The thesis ends with summaries in
English and Dutch.
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Lyme borreliosis:
an overview.
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Lyme borreliosis:
an overview.
In November 1975 a mother from Old Lyme, Connecticut, in the United States,
informed the State Health Department that 12 children from that small commu-
nity of 5,000 inhabitants, 4 of whom lived close together on the same road, had
a disease diagnosed as juvenile rheumatoid arthritis. During the same month
another mother from the same community reported to the Yale Rheumatology
Clinic and to the Health Department that she, her husband, 2 of their children,
and several neighbours all had arthritis. Again most of the children were thought
to have juvenile rheumatoid arthritis. Allen Steere, who had received training in
Epidemiology, performed subsequent studies of children and adults in that
geographic region, and suggested that "Lyme arthritis" was a previously unrec-
ognized clinical entity (1).
This epidemic form of arthritis occurred in eastern Connecticut from at least
1972, with a peak incidence of new cases in the summer and early fall. The
illness was characterized by recurrent attacks of asymmetric swelling and pain
in a few large joints, especially the knee. An erythematous papule that developed
into an expanding red, annular lesion, up to 50 centimeter in diameter, was
reported by 25% of the described patients. It was suggested that the disorder was
transmitted by an arthropod, an ixodes tick (2).
The expanding skin lesion fitted the description of erythema chronicum
migrans, already described by Afzelius and Lipschutz in Europe at the beginning
of this century (3,4). This skin lesion was thought to be caused by a tick, /jtodes
nci/iMS. It was already known that a chronic skin lesion, acrodermatitis chronica
atrophicans, could follow erythema migrans (5). Bannwarth from Germany had
defined a syndrome that consisted of radicular pain, chronic lymphocytic
meningitis and cranial or peripheral neuritis. In some cases this was preceded by
erythema migrans, and caused by ticks (6). Spirochete-like structures in skin
specimens of patients with erythema migrans were seen by Lennhoff in 1948
(7). Penicillin was used to treat the skin lesions (8). Arthritis had not been
associated with erythema migrans before.
It soon became clear that Lyme disease was a multisystem illness that could
affect the skin, nervous system, heart, and joints (9).
In November 1981, Willi Burgdorfer of the Rocky Mountain Laboratories of
the National Institute of Allergy and Infectious Diseases, discovered that the
etiological agent of Lyme disease was a spirochete (10). This spirochete was
12
found mainly in the midgut of ticks, /xorfes <famm<>ii. Alan Barbour succeeded
in growing the spirochetes in culture (11). The spirochete, now called fio/re/za
ftwrgrfoz/en', was then recovered from patients with Lyme disease in the United
States and Europe (12-16). The most common name for the disease is Lyme
disease or Lyme borreliosis.
Borrelia burgdorferi
burgrfor/en (fl. fcwrgc/or/m) belongs to the phylum of spirochetes.
Borrelia species have a protoplasmic cylinder that is surrounded by a cell
membrane, flagella, and by an outer membrane (17). It is a loosely coiled, left
handed helix. Genes encoding the outer membrane are located on plasmids, an
arrangement that may be advantageous to the organism in making antigenic
changes in these proteins (18).
fl. burgdor/èrz is the longest (20-30 ^m) and narrowest (0.2 to 0.3 nm) of its
species (19). It contains at least 30 different proteins, including the two major
outer-surface proteins, called outer-surface protein A (30 to 32 kd), and outer-
surface protein B (34 to 36 kd) (18,20-23). The 41-kd antigen is located on the
flagellum (24). The p-39 antigen is also a specific antigen, which stimulates
antibody production especially in late Lyme borreliosis (25). B. burgdor/m
grows, as fastidious, microaerophilic bacteria, at 33° Celsius in a complex, liquid
medium called Barbour-Stoenner-Kelly medium (11). 5. /wgdor/m grow
slowly; they elongate for 12-24 hours and then divide into two cells (11). After
10 to 15 passages, £. ÖMrgdor/èn loses pathogenicity in culture (26). After that
time, organisms are no longer infectious.
It is difficult to isolate fi. öwrgdor/ien from patients, but, relatively easy to do
so from ticks (12,13). The spirochete is only present in very small numbers in
mammalian tissue.
Certain differences have been noted between American and European isolates
of #. ÖMrgrfor/èrz' in morphology, outer surface proteins, plasmids, and DNA
homology (19,27-29).
Vector
r /m is transmitted by ixodes ticks that are part of the /jcodes rzc/rt«s
complex; in the north eastern United States, fexies <ftz/n/nz>ii, in the western
United States, zjcodes pacz/zcus, in Europe, foodes ric/nus, and in Asia, /.rodes
persM/carus (30-33). Only ticks from the Awcfes rici/ias complex seem to be
important in the transmission of the spirochete to humans.
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Figure 1. Erythema migrans
The life cycle of the ticks normally spans two years. Eggs are deposited in the
spring and hatch into free-living larvae a month later. During the first summer
the larva feeds once with the blood of a host and then enters a resting stage
coincident with the onset of cold weather in the fall. The following spring the
larva molts, enters a second immature stage, called the nymphal stage, and again
attaches itself to an animal host, to feed for another three or four days. The
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Figure 2. Erythema migrans
majority of the ticks are found on the white-footed mouse, /VrowyscMS /ew-
copwj. In this stage, they are likely to attack humans. At the end of the summer
nymphs molt into adults. They can be found in brush about one meter above the
ground, from where they can attach themselves to larger animals, predominantly
the white-tailed deer, O^oco//e«s virg/nia/titf. The adult male ticks mate on the
host soon after the female tick attaches herself to it. The males die soon after
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mating, and only the females hibernate. Eggs are deposited and the entire cycle
repeats itself. Humans may be infected during bloodmeals of the larvae,
nymphs, or adults. Transmission of spirochetes occurs when the tick is attached
for more than 48 hours (34).
Infection rates of ticks may be as high as 50 percent in /jtoofes <üam/n//ti ticks
on Shelter Island in the United States (12,35). In the Netherlands, infected ticks
could be found in most parts of the country. Infection rates varied from 2 to 30%
(36).
Epidemiology
Lyme disease is the most common vector-borne infection in the United States
(37). Most cases are described in the northeastern, midwestern, and western
parts of the country. In Europe, cases have been reported from most countries,
such as Great Britain, Germany, Sweden, Belgium, Italy, France and Austria,
and probably thousands of new cases occur each year (38). The exact incidence
and prevalence of Lyme borreliosis in the Netherlands are unknown. The
presence of antibodies to fi. èurgdor/i?n among Dutch blood donors varies from
2 to 17% (mean 8.7%) (39). Assuming a total Dutch population of 15,000,000
means that 1,305,000 people have positive antibodies. In a Swiss study, about
3% of people with positive antibodies have clinical Lyme disease (40). The
estimated prevalence of clinical Lyme borreliosis in the Netherlands is 39,150.
The estimated incidence of clinical Lyme borreliosis is 560 each year.
Clinical manifestations
Lyme borreliosis generally occurs in three stages, with different clinical mani-
festations at each stage (9). A modified plan was proposed by Asbrink, in which
the disease is divided into early and late infection (41). Early infection includes
stage 1 (erythema migrans), followed within days or weeks by stage 2 (second-
ary erythema migrans and disseminated infection), and within weeks or months
by intermittent symptoms. Late infection, or stage 3 (persistent infection),
usually begins a year or more after the onset of the disease. A patient may have
one or all stages, and the infection may not become symptomatic until stage 2
or 3 (42). Lyme borreliosis typically begins with erythema migrans, often
accompanied by constitutional symptoms, such as fever, lymphadenopathy,
fatigue and headache. Erythema migrans may expand with partial central clear-
ing or with central induration or vesicle formation. Erythema migrans is usually
located at the site of the tick bite (figure 1 and 2). After 3 to 4 weeks (range, 1
day to 1 year), erythema migrans lesions fade, even in untreated patients. A
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history of a tick bite at the site of the skin lesion can be a helpful clue, however,
only 50% of the patients remember being bitten by a tick. The initial skin lesion
may be followed by similar, but generally smaller, lesions. These secondary
lesions are probably due to a hematogenous or lymphatic spread (disseminated
disease, stage 2). Within a few weeks or months, about 15-25% of patients
develop clear neurological involvement, which may be accompanied by radicu-
lar pain, meningitis, cranial nerve involvement or peripheral neuropathy (43,44).
Cardiac abnormalities occur in 8-10% of the patients, most commonly in the
form of a fluctuating atrio-ventricular block (45). Acrodermatitis chronica
atrophicans is a late skin disorder caused by the spirochete (46). Joint symptoms
will be extensively discussed in the following section.
An overview of all manifestations of Lyme borreliosis is summarized in Table
1. This table is derived from an article by Steere, which gives an extensive
Table 1. Clinical manifestations of Lyme disease
System
Skin
Musculoskeletal
system
Neurological system
Heart
Lymphatic system
Eyes
Liver
Respiratory system
Kidney
Constitutional
symptoms
Localized (stage 1)
Erythema migrans
Regional
lymphadenopathy
Minor
Early infection
Disseminated (stage 2)
Secondary erythema migrans
Lymphadenosis benigna cutis
Migratory pain in joints,
tendons, muscle, bone; brief
arthritis attacks.
Meningitis, cranial neuritis.
Bell's palsy, motor or sensory
radiculoneuritis, encephalitis
Atrio-ventricular block,
myopericarditis, pancarditis
Regional or generalized
lymphadenopathy
Conjunctivitis, iritis
Hepatitis
Nonproductive cough
Microscopic hematuria or
proteinuria
Fatigue, malaise
Late infection
Persistent (stage 3)
Acrodermatitis chronica
atrophicans
Prologed arthritis attacks,
chronic arthritis, peripheral
enthesopathy, joint
subluxations below lesions of
acrodermatitis chronica
atrophicans.
Chronic encephalomyelitis,
spastic parapareses, mental
disorders, dementia
Keratitis
Fatigue
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review of the clinical manifestations of Lyme borreliosis (42). This thesis will
focus primarily on Lyme arthritis.
Lyme arthritis
A mean of six months after the onset of the disease (range, two weeks to two
years), commonly after intermittent episodes of arthralgia or migratory
musculoskeletal pain, about 60 percent of the patients in the United States begin
to have brief attacks of asymmetric oligo articular arthritis, primarily in the large
joints, and especially the knee (47). Episodes of arthritis often become longer
during the second and third years of the illness, lasting months rather than weeks.
Chronic arthritis—defined as a year or more of continuous joint inflammation—
characteristically begins during this period as well (47). Typically, only one or
a few large joints are affected, most commonly the knee. The clinical evolution
of Lyme arthritis has been described by Steere among 55 patients who had not
received antibiotic therapy for erythema migrans. These patients were followed
for a mean duration of 6 years (47). Of these 55 patients, 11 (20%) had no
subsequent manifestations of Lyme borreliosis at all. From one day to eight
weeks after disease onset, 10 of the patients (18%) began to have brief episodes
of joint, periarticular, or musculoskeletal pain lasting as long as six years, but
none developed objective joint abnormalities. From four days to two years after
disease onset, 28 (51 %) had one episode or began to have intermittent attacks of
arthritis, primarily in large joints. The duration of these episodes ranged from
three days to 11.5 months, with a mean of three months. Episodes of arthritis
were often separated by months or even years of complete remission. The total
number of these patients who continued to have recurrences, decreased by
10-20% each year. Six patients (11%) developed chronic synovitis.
Radiology
In 25 patients with severe arthritic manifestations the most frequent radiographic
finding was knee joint effusion (48). Intra-articular edema was often accom-
panied by a continuum of soft-tissue changes involving the infra-patellar fat pad,
periarticular soft tissues, and the entheses, which were sometimes thickened,
calcified, or ossified Late in the illness, the joints of some patients showed
typical changes o' a:i inflammatory arthritis, including juxta-articular osteo-
porosis, cartilage >ss, and cortical or marginal bone erosions. Less commonly,
patients demonstrate! characteristics of degenerative arthritis, including car-
tilage loss, subarticular sclerosis, and osteophytes (48).
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Synovium
In 17 patients with Lyme arthritis, synovial specimens, showed non-specific
villous hypertrophy, synovial cell hyperplasia, prominent microvasculature,
lymhoplasmacellular infiltration, and sometimes lymphoid follicles (49). Surgi-
cally obtained specimens also showed striking deposition of fibrin in synovial
stroma and a form of endarteritis obliterans. In 2 patients, spirochetes could be
demonstrated in and around blood vessels by the Dieterle silver stain. Compared
with 55 synovial specimens from cases with articular disease, obliterative
microvascular lesions were seen only in Lyme synovia; stromal deposition of
fibrin was a non-specific finding.
Immunology
A specific IgM response, often directed against the 41 -kd flagellar antigen of the
spirochete, peaks between the third and sixth week but may persist (12,50). This
specific IgM response is frequently associated with evidence of the polyclonal
activation of B cells, including elevated total serum IgM levels and the presence
of cryoprecipitations, circulating immune complexes, and occasionally, rheu-
matoid factor, antinuclear antibodies, or anticardiolipin antibodies (51-54).
Specific IgG antibodies develop after 6 to 8 weeks to different spirochetal
polypeptides, particular to the 31-, 34-, and 66-kd outer surface proteins, the
41-kd flagellar antigen, and the 55/58-kd antigen (50). Immune antibodies are
required for the serum-mediated killing of the spirochete by the classical com-
plement pathway (55). Polymorphonuclear leukocytes and monocytes readily
phagocytose and kill the spirochete. Histologically, all affected tissues show
infiltration of lymphocytes with plasma cells (56). IgG antibodies may persist
for years in patients with continuing infection.
B. öwrgdor/èn' is also capable of inducing a specific cellular immune re-
sponse. Antigen-specific responses are concentrated at the sites of inflammation.
The cellular immune responses are directed to multiple spirochetal polypeptides.
These responses, however, ranged from marked to minimal (57-58).
As with a number of rheumatic diseases, chronic Lyme arthritis appears to
have an immunogenetic basis involving D-locus alleles of the major histocom-
patibility complex. These class II histocompatibility molecules, which are lo-
cated primarily on B lymphocytes and macrophages, present peptide fragments
of foreign antigens to T helper cells that initiate the immune response against the
antigens. In a study of 80 patients with Lyme arthritis, those with chronic joint
involvement had a significantly increased frequency of HLA-DR4, often com-
bined with HLA-DR3 or DR2, and these patients often did not respond to
multiple courses of antibiotic therapy (59). It was concluded that in genetically
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susceptible people, 5. burgdor/èn may trigger an immune response with auto-
reactive features, that continues for some time after the organism has been killed.
The small number of spirochetes found in synovial tissue is probably the
antigenic stimulus for chronic synovial inflammation (60). Interleukin-1 and
Interleukin-1-producing cells are found in the synovial fluids of Lyme patients.
This Interleukin-1 is probably a major endogenous mediator of Lyme- and other
types of arthritis (61). Other cytokines like Interleukin-6 and tumor necrosing
factor may also contribute to the pathogenesis of Lyme arthritis.
Diagnosis
Lyme borreliosis is primarily a clinical diagnosis. At the tissue level, infection
with B. bwrgdor/m can rarely be proven, because of the scarcity of organisms
seen on histologic staining of affected tissues and the technical difficulty as-
sociated with culturing from clinical specimens (12). Only culturing from
erythema migrans is relatively easy (62). There are only 2 reports of a positive
culture from synovial fluids from patients with Lyme arthritis (63,64). Serologic
tests can only serve as an adjunct to a clinical diagnosis. False positive results
and asymptomatic infection are well known (40,65-67). Pitfalls of diagnostic
testing will be discussed in the general discussion section of this thesis.
Laboratory investigations
A specific immune response to fi. èwrgdor/en is detectable by indirect immuno-
fluorescence assay or an enzyme-linked immunosorbent assay (ELISA) (68).
ELISA's are preferred, because their sensitivity and reproducability are better
than those of immunofluorescence assays (69). As these methods are not stand-
ardized, serologic results should be interpreted with caution. The tests offered
by various laboratories differ in sensitivity and specificity (65-67). False posi-
tive results and considerable inter and intra laboratory variation have been
reported. At present, interpreting laboratory results is difficult unless one is
familiar with the reference laboratory used and its validation procedures (70).
In most ELISA's, extracts of sonicated whole fi. bwrgdor/ien are used as
antigens. There are several modifications of this technique such as an IgM
capture technique, adsorption of test serum with Escherichia Coli, and use of
purified flagellin protein (71-73). However, these modifications also vary
widely. True seronegativity is uncommon in patients with clinical manifesta-
tions of disseminated or chronic Lyme disease.
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Western blotting could be helpful in distinguishing true positive from false
positive ELISA results (74). To date, it is only used as a validation procedure.
The test is not widely available.
Cell-mediated Immunity testing has been used as a means of identifying
exposure to 5. öwrg6fc>r/i?n. The earliest immune response after the onset of
infection is a T-cell response (58). Clinical usefulness has not been confirmed
(88).
fi. bMrgdor/m antigens may be excreted in the urine of experimentally
infected animals and naturally infected humans (75). These urine antigen tests
have not been clinically validated and should not be used in the diagnosis of
patients with Lyme disease.
Polymerase chain reaction is under development for identification of spiro-
chetal DNA in patient tissues and fluids (76). This test also is not currently
available in the clinical situation.
Therapy
Lyme borreliosis is treated with antibiotics (77). Antibiotic sensitivities to fl.
burgdor/m have been determined in vitro and in experimental animals (78-80).
fi. 6wrgdor/i?n is highly sensitive to tetracycline, but only moderately to penicil-
lin. Ampicillin, ceftriaxon, and imepenem are also highly active against fl.
&wrgdo//<?n. Erythromycin is very active against the spirochete in vitro, but not
as effective /n v/vo.
Oral tetracycline or doxycycline are currently recommended as treatment for
early and mild Lyme disease (42,81). This includes isolated facial palsy and first
degree atrio-ventricular block (42). Too short a treatment period may result in
failure of therapy (82). Duration of therapy for early symptoms should be guided
by clinical manifestations and typically varies from 10-30 days (42). Intravenous
ceftriaxon is currently the treatment of choice for neurological abnormalities and
a high degree of atrio-ventricular block. Ceftriaxon is used, because it crosses
the blood-brain barrier more readily and only once-a-day or twice-a-day admin-
istration is required (42,83). For acrodermatitis chronica atrophicans, oral anti-
biotic therapy is usually adequate but prolonged courses with antibiotics can be
necessary. An overview of treatment recommendations for the different clinical
manifestations of Lyme borreliosis is given in Table 2. These recommendations
are subject to change as more clinical antibiotic trials will become available.
A Jarisch-Herxheimer reaction after antibiotic therapy is found in about 15%
of patients (9).
Prophylactic antibiotic treatment of tick bites is not recommended. The risk
of Lyme disease among people with a tick bite is low, even in endemic areas
(84-86).
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Table 2: Antibiotic therapy in Lyme borreliosis
Erythema migrans
Neurologic
abnormalities**
Cardiologie
abnormalities**
Arthritis
Acrodermatitis
chronica atrophicans
Antibiotic
Amoxicillin
Penicillin
Erythromycine
Doxycycline
Ceftriaxon
Penicillin
Ceftriaxon
Penicillin G
Doxycycline
Amoxicillin
Ceftriaxon
Doxycycline
Ceftriaxon
Route
oral
oral
oral
oral
iv
im
iv
iv
im
iv
oral
oral
iv
im
oral
iv
im
Duration*
14*
14*
21*
14*
14
14
14
14
14
14
30
30
14
14
30
14
14
Dosis
<12 years
20-40 mg/kg 3 x daily
50 mg/kg 3 x daily
20-40 mg/kg 4 x daily
100 mg/kg daily
2 divided dosis
100.000-
250.000U/kg/daily
4-6 doses daily
100 mg/kg daily
2 divided doses
100.000-250.000
U/kg/daily
4-6 doses daily
50 mg/kg 3 x daily
lOOmg/kg/daily
2 divided doses
>12 years
500 mg, 3 x daily
500 mg, 3 x daily
250 mg, 4 x daily
100 mg, 2 x daily
2 g daily
2 divided dosis
20 x 10^U/daily
4-6 doses daily
2 g daily
2 divided doses
20 x 10^
4-6 doses daily
100 mg, 2 x daily
500 mg, 3 x daily
2 g daily
2 divided doses
100 mg, 2 x daily
2 g daily
2 divided doses
* The duration of therapy is dependent on clinical response. Treatment failures have oc-
curred, and retreatment may be necessary; ** For facial palsy alone, and first degree
atrio-ventricular block, oral antibiotics may be adequate.
Treatment of Lyme arthritis
Lyme arthritis has been treated successfully with parenteral penicillin (87).
Forty patients with Lyme arthritis were treated either with placebo or penicillin
(2.4 million units of benzathine penicillin weekly for 3 weeks). Seven, out of 20
patients treated with penicillin responded fully, while none of placebo treated
patients did. Eleven of 20 patients treated with penicillin intravenously (20
22
million units daily for 10 days), responded slowly (87). Dattwyler treated 7
patients with recurrent oligoarthritis with penicillin (24 million units daily for
10 days) and compared the results with 9 ceftriaxon treated patients (4 grams
intravenously for 14 days) (83). Patients treated with ceftriaxon all responded,
whereas 5 patients treated with penicillin did not respond at all. He also treated
23 consecutive patients with Lyme arthritis with ceftriaxon, 4 or 2 gram in-
travenously daily for 14 days. Only 3 patients did not respond. Liu compared
two oral treatment regimens (88). Thirty eight patients were randomly assigned
to receive either doxycycline (100 mg orally twice daily) or amoxicillin and
probenecid (500 mg each orally four times daily) for 30 days. In the doxycycline
group, 13 of 18 patients (72%) responded compared to 11 of 18 patients (61%)
in the amoxicillin group. The latter group reported more side effects. In the same
study, 29 patients with recurrent or persistent arthritis despite oral antibiotic
therapy, were given either penicillin intravenously (20 million units daily for 14
days) or ceftriaxon intravenously (2 or 4 gram daily for 14 days). Results for
both treatment groups were disappointing. Only 5 out of 14 penicillin treated
patients (35%) responded, and only 6 out of 15 ceftriaxon treated patients (40%).
In a randomized therapeutic study, 18 patients with recurrent arthritis were
treated with penicillin (penicillin G 2 million units daily for 10 days) and 16
patients with cefotaxime ( 2 x 3 grams daily for 10 days) (89). Four of 18
penicillin treated patients (22%) responded, compared to 7 of cefotaxime treated
patients (44%).
These studies indicate that the optimal therapy for Lyme arthritis has not yet
been established (90). Initial treatment with an oral antibiotic is recommended,
preferably oral doxycycline 200 mg daily for 30 days. Since response to antibi-
otic therapy may take at least 3 months to occur, repetition with a second course
of doxycycline should not be initiated before 3 months have passed since the
first treatment. In patients with persistent arthritis, ceftriaxon intravenously can
be prescribed, however the response is hardly predictable.
Twenty patients underwent arthroscopic synovectomy for refractory chronic
Lyme arthritis of the knee (91). Sixteen (80%) had resolution of joint inflamma-
tion during the first month after surgery or soon thereafter, and they have
remained well during the 3-8 year follow-up period. The remaining 4 patients
(20%) had persistent or recurrent synovitis.
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ABSTRACT
A nation wide survey among all 118 Dutch rheumatologists (response rate 85%)
yielded 42 patients with Lyme arthritis. The arthritis was nonpersistent in all
these patients. A tick bite was reported by 23 of these 42 patients (55%).
Erythema migrans was recalled by 19 patients (45%). Cardiac manifestations
occurred in 4 patients (9%) and neurologic symptoms in 14 patients (33%). By
immunoabsorbent assay or immunofluorescence technique 37 patients (88%)
had positive IgG antibodies to fie>rre//a burgdcr/m. The distribution of HLA-
DR alleles of 28 of these patients was not different from the healthy population.
The response to antibiotic treatment was considered good in 34 patients (81%).
The clinical features of the Dutch patients with Lyme arthritis closely resemble
the description of the disease reported from the United States.
INTRODUCTION
Lyme borreliosis is a zoonosis caused by the spirochete Bo/re//a bwrgdor/ier/ (fl.
èurgfikw/eri), and transmitted primarily by /jcodes ft'cfo. In Europe the tick
species is /jcodes ricinus (1). The disease runs in 3 stages. Rheumatic manifesta-
tions occur in stage 2 as migratory pain in joints, tendons, bursae and brief
arthritis attacks. Late infection or stage 3 usually begins a year or more after the
onset of the disease with manifestations such as acrodermatitis chronica atroph-
icans, prolonged arthritis attacks, peripheral enthesopathy, chronic arthritis,
chronic encephalomyelitis and chronic axonal polyradiculopathy (2). A patient
may show all 3 stages, and the infection may not become symptomatic until
stage 2 or 3.
In the United States, about 60% of the patients with Lyme borreliosis ex-
perience brief attacks of asymmetric, oligoarticular arthritis, primarily in the
large joints, especially the knee (3). This occurs on the average 6 months (range
2 weeks to 2 years) after the onset of stage 1 of the disease and is commonly
preceded by intermittent episodes of arthralgia or migratory musculoskeletal
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pain. Involvement of the joints, however, is thought to be a less frequent
manifestation of the illness in Europe, although this is controversial (4-15).
The reported differences in the prevalence of Lyme arthritis between North
America and Europe might merely reflect differences in the awareness of Lyme
arthritis or may reflect rea/ differences in the occurrence of this disease (16).
Our purpose was (1) to investigate how frequently Lyme arthritis was diag-
nosed by Dutch rheumatologists; (2) to determine whether there are striking
differences in the clinical pattern of Lyme arthritis between the United States
and Europe, and (3) to assess the prevalence of HLA-DR antigens among Dutch
patients with Lyme arthritis.
METHODS
Survey
In May 1988 a survey was sent to all (n= 118) Dutch rheumatologists. They serve
a population of 15 million people. The questionnaire included items about the
diagnosis of Lyme arthritis, for example, how often a diagnosis of Lyme arthritis
was made, whether the diagnosis was confirmed by serology and in which part
of the country the disease was contracted.
The reported cases of Lyme arthritis were restudied by indepth chart review.
Whenever possible, patients were examined by one of the investigators (AB).
Patients were included if erythema migrans, Bannwarth syndrome or facial
palsy had been present preceding or simultaneously with rheumatic symptoms
such as arthralgia or arthritis. Patients with arthritis who had positive antibodies
to fi. fturgdor/m' without another definable cause for arthritis were also in-
cluded. These patients were felt not to have infectious arthritis, psoriatic arthri-
tis, ankylosing spondylitis, rheumatoid arthritis, systemic lupus erythematodes,
crystal induced arthritis and reactive arthritis. In addition, patients known to
have sacroiliitis or Reiter's syndrome were also excluded. Antibodies to fi.
/ m had been determined at the rheumatologist's local laboratory.
Serology
We restudied these patients and new serum specimens were obtained. These sera
were tested in our laboratory for the presence of IgG antibodies to fl. öwrg<fo//<?n
by an immunofluorescence assay (IFA) as well as an enzyme linked immuno-
sorbent assay (ELISA) (17).
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ELISA
The ELISA was performed essentially as described by Craft, ef a/ (18). For
interpretation of the test results a cutoff value of 0.35 was calculated. This
optical density value was 2 standard deviations above the mean value of 128 sera
from Dutch healthy laboratory staff members.
IFA
The IFA was performed as described by Wilske é7 a/ (19). Based on the results
for 128 Dutch healthy laboratory staff members the cutoff level after adsorption
with 7Veponema p/jageden/s was at a titer of 1:64 (specificity 98%).
HLA-antigens
Twenty-eight patients could be tissue typed for their HLA-DR antigens by
means of the 2-color fluorescence test and a set of 120 platelet-absorbed sera
(20). Sixteen DR specificities (DR1-DR16) were tested for. A panel of 500
random Dutch Caucasian blood donors was used as healthy controls.
RESULTS
One hundred of the 118 questionnaires were returned (85%). Forty nine cases of
Lyme arthritis were reported by 20 Dutch rheumatologists. Seven cases did not
meet our inclusion criteria and were excluded from the study. Thirteen rheuma-
tologists reported 1 patient each. Three rheumatologists reported 2 patients, one
3 patients and one 4 patients. Two rheumatologists reported 8 patients each. The
42 patients were restudied by clinical chart review and 24 of them (57%) were
examined personally by one of us (AB). The male to female ratio was 1:1. The
mean age of the patients was 40 years (range 14-72 years) at time of diagnosis.
Seven patients had jobs like foresters or farmers that might expose them to fl.
ÖM/gdor/eri at a higher rate.
The infections were reported from all parts of the country. However, 15
patients (36%) came from the middle-east part and 13 patients (31%) from the
south east part of the country.
Thirty of the 42 patients presented to their rheumatologists with arthritis, 12
complained about severe arthralgia (figure 1). Of the 30 patients with arthritis,
16 showed other manifestations that could be ascribed to Lyme borreliosis. Of
these 16 patients, 13 patients showed positive antibodies to fl.
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30 arthritis
16 extra-articular manifestations
12aithralgia I 12 extra-articular manifestations
13 antibody +
2 antibody -
1 not done
14 no extra-articular manifestations | 14 antibody +
42 patients
10 antibody +
2 antibody -
Figure 1. Distribution of symptoms and signs in 42 Dutch patients with Lyme arthritis
(range ELISA 0.65-1.64, range IFA 1:256-1:2048). In one of the 3 remaining
patients no serologic test was performed. She had atrial fibrillation and oligoar-
thritis after a tick bite in 1979. One patient did not have positive antibodies to fl.
owrgdor/m. He presented with arthritis of the knee and classical Bannwarth
syndrome (neuroborreliosis). Another patient, also seronegative, developed
arthritis of her ankle joints 3 weeks after a tick bite and in spite of antibiotic
treatment for erythema migrans. Fourteen patients with arthritis had no other
Lyme symptoms, they all had positive antibodies to fl. /?«r^or/<?n (range
ELISA 0.74-1.95, range IFA 1:256-1:2048).
Arthritis was localized in the knee joint in 20 patients (48%), 10 of them with
no other symptoms of Lyme borreliosis.
In 14 cases arthritis was monarticular. Other affected joints were ankles (7
cases), hands (7 cases), wrists (6 cases), elbow (4 cases), feet (4 cases), shoulder
(1 case) and hip (1 case).
The 12 patients with severe arthralgia showed other symptoms that could be
ascribed to Lyme borreliosis (figure 1). Ten of these 12 patients had positive
antibodies to fl. owrgdor/m (range ELISA 0.67-1.30, range IFA 1:128-1:1024).
Two of these 12 patients complained about arthralgia following erythema
migrans, but showed no positive antibodies to fl. b«rg<ior/<?n.
A history of a tick bite was reported by 23 patients (55%). Nineteen of the 42
patients recalled erythema migrans (45%). The tick bite definitely preceded
erythema migrans in 14 patients.
Cardiac manifestations, second degree or total atrioventricular block, atrial
fibrillation and sinus bradycardia, were documented in 4 patients (9%).
Fourteen (33%) patients had neurologic symptoms, 6 of them after erythema
migrans. Neurological syndromes included severe radicular pain (5 cases),
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paresthesia (4 cases), polyneuropathy (one), Bannwarth syndrome (one), Bann-
warth syndrome and facial palsy (one), acusticus neuritis (one) and facial palsy
(one).
No late skin manifestations such as acrodermatitis chronica atrophicans had
occurred among the 42 patients.
HLA antigens
HLA-DR determination could be done for 28 of the 42 (66%) patients. No
significant differences in HLA-DR frequencies of 28 patients with Lyme ar-
thritis compared to the controls were found (table 1). The HLA-DR4 specificity
was found in 6 Lyme patients (21%), the HLA-DR2 specificity in 8 Lyme
patients (28%).
HLA-DR4 in association with DR2 was found in one patient. However, none
of the 28 studied patients showed chronic arthritis.
Table 1. Prevalence of HLA-DR antigens in patients with Lyme arthritis and in Caucasian
blood donors.
Lyme arthritis
n=28
controls
n=500
DR1
DR2
DR15
DR16
DR3
DR4
DR5
DR11
DR12
DR6
DR13
DR14
DR7
DR8
DR9
DR10
28%
28%
28%
—
18%
21%
18%
11%
7%
39%
36%
3%
18%
8%
7%
—
19.4%*
25%
21.5%
3.5%
21.2%
24.6%
24.8%
20.4%
4.4%
33.6%
25.3%
8%
23.4%
6.8%
2.8%
2.6%
*RR 1.8
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Antibiotic Treatment
All but 2 of the 42 patients were treated with antibiotics. The 2 untreated patients
had recovered spontaneously after several weeks. Ten patients had received
20-24 million units penicillin/day intravenously for 10-14 days. Eight of them
recovered. After this therapy one patient complained about persistent arthralgia
and fatigue and received a second course of penicillin therapy without improve-
ment. However, after ceftriaxone intravenously she recovered within 2 weeks.
The other patient showed persistent arthritis of his knee joint after penicillin
therapy. His arthritis resolved after oral doxycycline for 30 days. Two patients
recovered after oral penicillin therapy. Only 2 of 25 patients treated with oral
tetracycline or doxycycline did not respond to this therapy. One of these two
patients still complained about arthralgia even after a second course of 30 days
doxycycline. The other patient recovered from his knee arthritis after ceftriaxone
intravenously. Three patients were treated with ceftriaxone intravenously. One
responded immediately, another responded very slowly. One patient could not
tolerate ceftriaxone and was treated with doxycycline orally.
Overall response to therapy was adequate in 34 of 39 patients. Five patients
still complained about arthralgia and fatigue. The response to antibiotic treat-
ment was unknown for 3 patients.
DISCUSSION
There are striking differences in the reported prevalence of rheumatic manifes-
tations of Lyme borreliosis, between various countries, especially between the
United States and Europe. Arthritis is said to be a common manifestation of the
disease in Germany, Switzerland and Belgium (12,13,16). Other studies also
from Europe, have reported considerably lower prevalence of rheumatic mani-
festations of Lyme borreliosis (4-15).
Several reasons have been proposed for these differences. First of all, a
diversity between American and European isolates of B. ÖMrgdo//<?n' has been
pointed out (4). Secondly, early (versus late or no) treatment of erythema
migrans could have prevented the development of arthritis (21). Thirdly, a lack
of diagnostic awareness of Lyme borreliosis or its rheumatic manifestations
could be responsible for the reported differences (16).
The present study was performed to determine how frequently a diagnosis of
Lyme arthritis was made by Dutch rheumatologists and to determine the clinical
spectrum of the disease. Our study supports the view that the incidence of
nonrheumatic manifestations in our Dutch patients is quite comparable to
reported findings. Of the 42 patients with Lyme arthritis, 9% showed cardiac
abnormalities and 33% neurological symptoms, whereas in the US comparable
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figures have been reported: 4-8% had cardiac involvement and 15-20%
developed neurologic manifestations (22,23). All patients studied presented
themselves primarily to rheumatologists. At this time it is impossible to say
whether there are real differences in the incidence of rheumatic manifestations
of Lyme borreliosis. In the US about 60% of patients with untreated erythema
migrans develop brief attacks of asymmetric oligoarthritis, commonly after
intermittent episodes of arthralgia or migratory musculoskeletal pain (3). It is
unlikely that such data from Europe will ever become available. However, it is
still possible to compare the incidence of Lyme arthritis after antibiotic treat-
ment of erythema migrans. Until such data exist no reliable conclusions about
real differences in the incidence of rheumatic manifestations of Lyme borreliosis
can be drawn.
Nonetheless our study also supports the view that major clinical or serological
differences regarding rheumatic Lyme manifestations between the US and the
Netherlands do not exist (16). Most patients with Lyme arthritis in the US have
raised IgG antibody titer to fi. ÖMrgdo//<?n' (3). In our study 37 of 42 patients
(88%) showed positive IgG antibodies to fi. ÖMrgdo//<?n' either in IFA or ELIS A.
The 5 patients who did not have positive antibodies either at time of diagnosis
or at time of survey were nonetheless clinically thought to have Lyme borrelio-
sis. Prompt antimicrobial therapy, as was done in 4 of these 5 patients could have
aborted the development of a mature humoral response or have arrested the
evolution of the antibody response (24).
As in other reports the knee was the most frequently affected joint (3). Indeed,
the clinical signs and symptoms of the 42 patients in this study fit the description
of Lyme borreliosis in the US. Since our survey was completed new cases of
Lyme arthritis are more frequently reported. Therefore Lyme arthritis was
probably underdiagnosed in the Netherlands.
Our study has not been designed to specifically assess the effects of antibiotic
treatment of Lyme arthritis. Treatment results of these patients should therefore
be interpreted with caution since recurrence of Lyme arthritis after antibiotic
treatment has been described (25).
However, the recovery of patients with Lyme arthritis after antibiotic treat-
ment reinforces the importance of early diagnosis of the disease and the potential
to reduce the burden of illness due to Lyme borreliosis successfully. Especially
if arthritis of unknown etiology is localized in the knee joint, Lyme arthritis
should be considered a possible diagnosis.
As with a number of rheumatic diseases, chronic Lyme arthritis appears to
have an immunogenetic basis involving D-locus alleles of the major histocom-
patibility complex (26). Chronic Lyme arthritis is associated with HLA-DR4 or
DR2 alleles. None of the 28 patients typed for HLA-DR antigens had chronic
persistent arthritis. The distribution of HLA-DR frequencies in our patients were
about the same as in the healthy population.
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In conclusion, Lyme arthritis has been diagnosed regularly by Dutch rheuma-
tologists although the disease may have been underrecognized in the past. The
clinical pattern of Lyme arthritis in 42 Dutch patients closely resemble the
pattern described in the literature. Rheumatologists should be aware of Lyme
arthritis as a highly treatable condition.
The authors wish to acknowledge the Dutch Rheumatologists and Drs. van
Hulsteijn, Alleman and Venenkamp for their cooperation in this study. We thank
MA Khan for critically reading the manuscript and providing helpful comments.
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Lyme borreliosis:
a very infrequent cause of arthritis of
undetermined etiology in the southern
part of the Netherlands.
ABSTRACT
Seventy-three patients with undiagnosed arthritis of undetermined etiology, 94
patients with classified arthritis (rheumatoid arthritis, ankylosing spondylitis
etc.) and 70 controls were studied for clinical and serological manifestations of
Lyme borreliosis. The patients were recruited from the three rheumatology units
in the most southern part of the Netherlands. A clinical diagnosis of poss/We
Lyme borreliosis was made in seven of 73 patients with arthritis of undetermined
etiology, in four of 94 patients with classified arthritis and in one of the controls.
A cte/ï/jite diagnosis of Lyme borreliosis could be made in only one patient who
belonged to the arthritis of undetermined etiology group. This patient had
erythema migrans, arthritis of the knee joint and showed positive antibodies to
fl. frMrgdor/m. In the southern part of the Netherlands, Lyme arthritis does not
seem to be a frequent cause of arthritis of undetermined etiology.
INTRODUCTION
Lyme borreliosis is a zoonosis caused by the spirochete flo/re/ia bwrgdor/en (fl.
fewrgdoz/m,). In Europe the disease is transmitted primarily by /xodes n'cmws
ticks (1). Migratory pain in joints and brief, or in later stages prolonged or
chronic, arthritis attacks, are reported as frequent rheumatic symptoms of Lyme
borreliosis (2,3). The musculoskeletal symptoms may occur without preceding
erythema migrans, cardiac or neurological symptoms (4).
In The Netherlands determination of antibodies to fi. /JMrgcfor/eri is not
routinely performed in patients with arthritis of undetermined etiology. There-
fore, there is a possibility that unrecognized cases of Lyme borreliosis may be
present among such patients. Indeed, to date a few cases of Lyme arthritis have
been reported (5,6). But in a nationwide survey in the Netherlands 18 patients
have been described who had positive antibodies to fl. burgdor/m together with
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arthritis or severe arthralgia but who had no other clinical features of Lyme
borreliosis (7). Early diagnosis of Lyme arthritis may reduce the burden of
illness and will prevent later stages of the disease. Lyme arthritis is a curable
disorder in the majority of cases (8-10).
In the present study patients with arthritis of undetermined etiology, were
studied by questionnaire and interviewed for clinical manifestations suggestive
of Lyme borreliosis. These patients were studied together with healthy controls
and patients who had classified arthritis. In addition, the prevalence of positive
antibodies to fi. öu/^dor/èn'was determined.
PATIENTS AND METHODS
Patients with arthritis of undetermined etiology
In 1989 consecutive patients with arthritis of undetermined etiology were
recruited from three rheumatology units: the Maasland Hospital Sittard, de
Wever Hospital Heerlen, and the University Hospital Maastricht, The Nether-
lands. These three hospitals are situated in the most southern part of the
Netherlands and they provide rheumatic care to the entire population living in
this part of the country.
All adult patients with mono-, oligo- as well as polyarticular acute or chronic
arthritis of undetermined etiology were included in the study. The diagnosis of
arthritis of undetermined etiology was based upon the judgement of the rheuma-
tologist of the participating center. In particular, these patients were felt not to
have infectious arthritis, psoriatic arthritis, ankylosing spondylitis, rheumatoid
arthritis, systemic lupus erythematodes, crystal induced arthritis and reactive
arthritis according to existing criteria (11-15). For the purpose of this article such
diagnoses are collectively labelled as classified arthritis. Patients considered by
their physician as having seronegative rheumatoid arthritis and who fulfilled the
1987 ACR criteria were included in the classified arthritis group.
Controls
Consecutive adult patients with classified arthritis served as a first control group.
The second control group consisted of healthy family members of patients with
arthritis of undetermined etiology and of healthy laboratory staff members.
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Questionnaire
Four different pictures of erythema migrans but not of other skin diseases were
shown to all patients and controls. They were asked whether they had ever had
a skin disorder as shown on these pictures. Explanation about the clinical
evolution of erythema migrans was provided by the rheumatologist if felt
necessary. All patients filled out a questionnaire regarding the number of
recalled tick bites, and about outdoor activities. In addition neurological, cardiac
and musculoskeletal manifestations suggestive of Lyme borreliosis were
assessed.
A presumptive clinical diagnosis of Lyme borreliosis was based upon this
questionnaire. For all patients and controls a clinical diagnosis of possible Lyme
borreliosis was made if arthritis had been preceded by erythema migrans, heart
block or neurological symptoms. None of the healthy controls had had rheu-
matic problems in the past. A clinical diagnosis of possible Lyme borreliosis was
made in all cases without prior knowledge of antibody titers to fl. ÖMrgdor/èn.
A definite diagnosis of Lyme borreliosis was made if the possible clinical
diagnosis of Lyme borreliosis was confirmed by a positive antibody titer to fi.
Serology
Blood samples from all patients and controls were tested for #.
specific IgG antibodies by an enzyme linked immunosorbent assay (ELISA) as
described elsewhere (16,17).
A cut-off value of 0.35 was calculated. This optical density value was 2
standard deviations above the mean value of 128 sera from Dutch healthy
laboratory staff members.
Statistics
For categorical data a X^ test was used to test for significant differences between
groups at an alpha level of 0.05.
Ethics
The protocol was approved by the Ethics Committee of the University Hospital
Maastricht. All patients had given written informed consent.
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RESULTS
A total of 237 patients were studied; 73 patients suffered from arthritis of
undetermined etiology. The mean age of this group was 45 years (range 18 to
73). The male to female ratio was 1:1. Ninety-four patients with classified
arthritis had a mean age of 51.8 years (range 11 to 79). The male to female ratio
in this group was 1:1. Also 70 healthy persons were tested. The mean age in this
group was 39.2 years (range 18 to 77). The male to female ratio was 2.8:1.
Of the 73 patients with arthritis of undetermined etiology, 29 showed monar-
f/ir/fw. In 17 of these the knee joint was affected and in five the ankle. The other
affected joints were hip (one patient), wrist (one patient), metacarpophalangeal
joints (three patients), manubriosternal joint (one patient) and proximal inter-
phalangeal joints (one patient).
Thirty-three patients suffered from o/jgoarf/ïntó which was localized in the
upper extremities in 11 patients, in the lower extremities in eight patients and in
both in 14 patients. In eight of these 33 patients (or 24%) the knee was among
the affected joints.
Eleven patients showed po/yartfinï/s of both upper and lower extremities.
Seven of the 73 patients reported they recognized erythema migrans from the
pictures shown to them. Five of these seven patients suffered from monarthritis
(knee, 3 cases; ankle, one case; metacarpophalangeal joint, one case), two had
oligoarthritis. Based upon this recognition a clinical diagnosis of possible Lyme
arthritis was made.
Only one patient who had arthritis of his knee joint and who reported to have
had erythema migrans, showed a high titer of antibodies to fl. burgdor/ên. A
definite diagnosis of Lyme arthritis was made in this case. The patient was
treated with doxycycline 200 mg/day during 30 days. At examination 4 months
later all signs of arthritis had subsided. The other six patients had no elevated
IgG antibodies to fi. bwrgdor/en.
Three of the 73 patients with arthritis of undetermined etiology showed
borderline positive IgG antibodies (ELISA titer 0.39, 0.43 and 0.43) to fl.
öurgdor/èn. These patients did not report any other (non-articular) manifesta-
tions of Lyme borreliosis. The arthritis of these three patients was localized in
ankle, knee and metacarpophalangeal joints. The patient with ankle arthritis
subsequently developed rheumatoid factor negative polyarthritis with sym-
metric involvement of metacarpophalangeal and proximal interphalangeal
joints. The other two patients had been successfully treated with non-steroidal
anti-inflammatory drugs. Until now, none of these patients developed any other
features of Lyme borreliosis.
Also, 94 patients with classified arthritis were studied: 44 patients had
seropositive rheumatoid arthritis, 17 seronegative rheumatoid arthritis, nine
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Table 1. Results of the clinical diagnosis and serology in patients with arthritis of undeter-
mined etiology, classified arthritis and controls.
Diagnosis
Arthritis of
undetermined etiology
Arthritis classified
Controls
Number
73
94
70
Possible clinical
Lyme
Borreliosis
possible: 7
no: 66
possible: 4
no: 90
possible: 1
no: 69
Positive antibodies
(ELISA>0.35)
1
3
1
1
0
4
Definite
Lyme
Borreliosis
1
0
0
0
0
0
psoriatic arthritis, eight gout, six HLA-B27 related peripheral arthritis, five
systemic lupus erythematodes and five reactive arthritis.
Four of the 94 patients with classified arthritis recognized erythema migrans
from the pictures. They had definite seronegative rheumatoid arthritis (2
patients), psoriatic arthritis or HLA-B27 associated arthritis. One of these
patients (who was considered to have seronegative rheumatoid arthritis) showed
a marginally elevated IgG antibody titer (ELISA 0.38). Because he had sym-
metrical erosive polyarthritis localized in hand and feet, he was not considered
to suffer from Lyme arthritis. Another patient with seronegative rheumatoid
arthritis showed a IgG antibody titer of 0.41 without any other sign or symptom
which could be ascribed to Lyme borreliosis. Therefore, in this case a diagnosis
of definite Lyme arthritis was also rejected.
From the group of 70 healthy controls one person recognized erythema
migrans, but did not show positive IgG antibodies. Two asymptomatic cases
showed slightly elevated IgG antibody titer (ELISA 0.37 and 0.38). One case
showed a titer of 0.50 without Lyme symptoms. Another person showed a high
titer of positive IgG antibodies (ELISA 1.06). He did not recall any symptoms
of Lyme borreliosis. Therefore, four of 70 controls (5.7%) had positive ELISA
serology. They were felt not to have clinical Lyme borreliosis and were therefore
not treated.
The results among the three groups are summarized in Table 1.
The occurrence of positive antibodies in the arthritis of undetermined etiology
group (5.4%) was not statistically significant different from the prevalence of
positive antibodies in the combined control group (classified arthritis patients
and healthy controls (3.7%) (p>0.5).
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DISCUSSION
Musculoskeletal symptoms as arthritis may occur in Lyme borreliosis without
preceding erythema migrans, cardiac or neurological symptoms (2,7,18). Al-
though differences in the clinical characteristics of Lyme borreliosis in Europe
and North America have been suggested, this might reflect a lack of awareness
of Lyme arthritis in Europe (3). Indeed, in a Danish study six cases of Lyme
arthritis were detected among 126 patients with oligoarthritis or seronegative
polyarthritis (18). These authors warn against underestimation of the occurrence
of Lyme arthritis since in three of these six cases arthritis was the first presenta-
tion of the disease.
The present study was performed to investigate whether Lyme arthritis might
have been undetected among patients with unclassified arthritis.
In our country serologic testing for antibodies to B. ÖMr^ rfor/i?n' is not usually
performed in patients with arthritis of undetermined etiology. Therefore, Lyme
arthritis may pass unnoticed.
Ten of 237 patients and controls in this study showed positive antibodies to
fl. ö«rgrfo//<?n' (4.2%). This is fully comparable to the percentage positive
antibodies in a population of blood donors from the same area (3%) (unpub-
lished findings). Also, no significant difference was found in the percentage
positive antibodies in the arthritis of undetermined etiology group compared to
patients with classified arthritis or healthy controls.
In the arthritis of undetermined etiology group a definite diagnosis of Lyme
borreliosis could be made in only one patient according to our criteria set for this
study. Three patients in this group showed marginally positive antibodies to B.
fr«rg(i0//<?n. However, clinically they were not felt to have Lyme arthritis.
In the classified arthritis group also two patients with seronegative rheuma-
toid arthritis showed slightly elevated antibodies. We do not consider these two
patients to have Lyme arthritis. In addition, four patients from the healthy
controls showed positive antibodies without any symptoms of Lyme borreliosis.
They were also not felt to have Lyme borreliosis.
A few points should be stressed. Pictures of erythema migrans in four
different stages were shown to all patients. The validity of this diagnostic
instrument is not clear. Twelve of the 237 subjects (5%) thought they recognized
erythema migrans from these pictures, seven patients of the arthritis of undeter-
mined etiology group, four of the classified arthritis group and one of the healthy
controls. In none of these cases a diagnosis of erythema migrans had been
previously confirmed by a physician. Only pictures of erythema migrans were
shown and pictures of other red annular cutaneous lesions were not included
among the photographs. Recognition of erythema migTans could therefore have
been biased. Indeed, overestimation of the true prevalence of erythema migrans
should be taken into account in studies such as this one. Strikingly, only one of
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the patients who recognized erythema migrans from the pictures showed posi-
tive antibodies to fl. /n/rgdor/m.
One might argue whether the low prevalence of Lyme arthritis among cases
of arthritis of undetermined etiology might be due to a selection bias. Patients
with Lyme arthritis might have been diagnosed before the study started and
could therefore not have been included in the group "arthritis of undetermined
etiology". We feel this is unlikely because our study was performed in 3
hospitals. Lyme arthritis has not been diagnosed in these centres in the last 5
years before the study.
In summary, a diagnosis of definite Lyme borreliosis could be established in
only one of 73 patients with arthritis of undetermined etiology based upon
previous erythema migrans, arthritis of the knee joint and strongly positive IgG
antibodies to B. burgdor/m.
Although we had postulated that at least in the southern part of The Nether-
lands the occurrence of Lyme arthritis might be underestimated, based on this
study, Lyme arthritis does not seem to be a frequent cause of arthritis of
undetermined etiology. Nonetheless, appropriate questions concerning past non-
articular signs and symptoms of Lyme borreliosis should be asked to any patient
with arthritis of undetermined etiology. We feel that routinely performing
serological tests for Lyme borreliosis in patients without Lyme signs or symp-
toms, can not be recommended in a setting with a low prevalence of Lyme
arthritis as in this study. However, Lyme borreliosis should be considered in the
differential diagnosis of arthritis because antibiotic treatment usually is highly
effective. Progression of joint damage or other manifestations which occur in
the later stages of the disease may be prevented if appropriate treatment is
provided immediately after the diagnosis Lyme borreliosis is established.
The authors wish to thank Drs. HM van Santen-Hoeufft, H Houben and H van
der Tempel for their support and cooperation in this study and MA Khan for
helpful comments and critically reading the manuscript.
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Is there any evidence for an
association between ankylosing
spondylitis and
infection?
ABSTRACT
The suggested relationship between 5orre//a bargdor/en' and seronegative
spondylarthropathies has been studied in 125 patients with ankylosing spondyli-
tis (AS). IgG antibodies to flo/refta ÖMrgdor/m were present in 11 of 125
patients (8.8%) and in 25 of 125 controls (20%). No patient had clinical Lyme
borreliosis. HLA-B27 status was known for 82 patients with AS. There was no
difference between B27+ and B27- patients. This study provides no evidence
that fiorre//a ÖMrg£/e>r/(?n' is associated with AS.
INTRODUCTION
In Lyme borreliosis, which is caused by the tick-borne spirochete
fcwrgdor/i?n ffl. frurgrfoz/erO, the musculoskeletal system is often involved (1).
Migratory pain in joints, tendons and bursae, brief arthritis attacks and in later
stages prolonged arthritis attacks, chronic arthritis and peripheral enthesopathy
are frequent symptoms of this disease (2).
Recently, it has been suggested that the spirochete fl. /3«rg<ior/i?n might
trigger reactive arthritis in a genetically susceptible HLA-B27 positive host (3).
This finding may have therapeutic implications and raises challenging new
questions about pathogenetic mechanisms underlying the spondylarthropathies
(4). Ankylosing spondylitis (AS) is the prototype of this group of disorders.
Indeed, spinal involvement and sacroiliitis have been ascribed to patients with
chronic fi. öwrgdo//<?n infection (5,6). Also, positive antibodies to fl. burg-
dorfen were found more often among Swiss patients with AS than among their
HLA-B27 positive relatives (7). However, these patients with AS were on
average older than the relatives, i.e. they might have been exposed longer to
infected ticks. Therefore, no definite conclusions could be drawn about the
clinical significance of antibodies to #. fewrgdor/en for the etiology of AS.
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In patients with AS we assessed (1) the presence of clinical manifestations of
Lyme borreliosis and (2) the prevalence of IgG antibodies to B. ÖHrgdor/m. Our
findings were compared with age matched controls.
MATERIALS AND METHODS
Patients and controls
Patients with AS (modified New York criteria) from the outpatient departments
of rheumatology of the University Hospital of Leiden, the Medisch Spectrum,
Alkmaar, and the Gemini-Hospital of Den Helder, were interviewed for clinical
manifestations of Lyme borreliosis (8).
Several pictures of erythema migrans were shown to all participants. A
standardized questionnaire assessing tick bites, cardiac, neurologic, musculo-
skeletal manifestations, and outdoor activities was completed (9). Whenever felt
necessary, additional explanation about the clinical evolution of erythema mi-
grans and about signs and symptoms of Lyme borreliosis was provided by the
interviewers. If the patients' responses suggested signs or symptoms of Lyme
borreliosis in the past, clinical records and correspondence were studied, and
patients' physicians were consulted.
A clinical diagnosis of Lyme borreliosis was made only if the patients had
erythema migrans confirmed by a physician, or if they had Bannwarth's syn-
drome or atrioventricular block of otherwise unknown origin. Patients with AS
with peripheral arthritis were not considered to have Lyme borreliosis unless
they had at least one nonrheumatic manifestation of Lyme borreliosis.
The controls consisted of male, age matched healthy laboratory and hospital
workers; patients from the outpatient department of rheumatology of the Uni-
versity Hospital of Leiden with non-inflammatory joint or muscle complaints;
patients with coronary heart disease from the outpatient department of cardi-
ology of the University Hospital Leiden; and blood donors from the same
geographic region. For practical reasons the control group consisted of only
men. In a previous study we have shown that gender does not influence
seropositivity for Lyme borreliosis (10). A subgroup consisting of patients of the
department of rheumatology and healthy laboratory and hospital workers (n=34)
was also interviewed and completed the questionnaire for clinical features of
Lyme borreliosis.
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Serology
Serum (10 ml) was obtained by venipuncture from all patients and controls.
Serum samples were tested for fi. o«rg<i0//<?ri specific IgG antibodies by an
enzyme linked immunosorbent assay (ELISA) as described elsewhere (11,12).
As cutoff value an optical density (OD) of 0.35 was calculated. This value was
2 standard deviations (SD) above the mean value for 128 sera of Dutch healthy
laboratory staff members and corresponded to the 95% specific cutoff value
based on the results of these sera (10).
Western blotting
Western blots were performed for all ELISA IgG positive antibodies from
patients with AS and controls (13). Western blot was considered positive when
a 41 kDa band was present in combination with either a 94 kDa and a 31 kDa
band or with a 31 kDa band and another band in the range of 18-40 kDa.
Statistics
For categorical data a X^ test was used to test for significant differences between
groups. A probability value < 0.05 was considered statistically significant.
The study was approved by the Ethics Committee of the University Hospital
of Leiden.
RESULTS
During the summer of 1990, a total of 125 patients with AS were interviewed
for clinical features of Lyme borreliosis. 95 were men (76%) and 30 women. The
mean age of these patients was 43.8 years with a SD of 10.0 years. The mean
duration of the disease was 7.5 years (SD 7.4 years).
The controls consisted of 125 individuals: 13 patients of the outpatient depart-
ment of rheumatology, 21 hospital workers, 47 patients of the outpatient clinic
of cardiology and 44 blood donors. The mean age of this group was 44.4 years
(SD 9.5 years).
The results of the reported clinical symptoms were compared to the presence
of IgG antibodies to fl. owrgdor/m (Table 1).
Erythema migrans was recognized from the pictures by 8 patients with AS.
However, erythema migrans was not confirmed by a physician. No patient had
been treated with antibiotics for the skin lesion. No antibodies to fi.
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Table 1. Results of the reported
/>«/-gd0//<?n' in 125 patients with AS
Lyme symptoms reported
No Lyme symptoms reported
Total
clinical symptoms compared to IgG
Antibodies to B. fcargdorfen'
Positive
0
11
11
Negative
12
102
114
antibodies to fl.
Total
12*
113
125
* None of these 12 patients had Lyme disease.
could be detected. Therefore, these 8 patients were not considered to have Lyme
borreliosis.
No patient with AS reported past cardiac symptoms such as heart block or
other rhythm disturbances. Four patients who reported to have had Bell's palsy,
had no antibodies to fi. bwrgdor/en.
Eleven patients with AS who did not report clinical manifestations of Lyme
borreliosis had positive antibodies to B. èurgdor/en'. OD values of the seroposi-
tive patients ranged from 0.35-0.68. Western blots of these 11 patients were
negative.
HLA-B27 status was known for 82 (65.6%) of the 125 patients with AS. Eight
(10.8%) of 74 B27+ patients had antibodies to fl. £wgcfc>r/i?n compared with 1
(12.5%) of 8 B27- patients (NS).
Twenty-five controls (20%) had antibodies to fi. bwrgdor/m. The OD values
of the seropositive controls ranged from 0.35-1.06. Western blots were per-
formed for all 25 seropositive controls: 2 healthy controls had positive blots
(ELISA 0.50 and 1.06). They denied any symptoms of Lyme borreliosis. The
percentage positive antibodies in the control group was significantly higher than
in the patients with AS (P<0.02).
Two individuals of the interviewed controls (n=34) recognized erythema
migrans from the pictures. They did not have antibodies to fl. 6argrfor/en. No
other signs or symptoms suggesting Lyme borreliosis were reported in this
group.
Overall, none of the 125 patients with AS were thought to have clinical Lyme
borreliosis, although 11 (8.8%) patients did have positive antibodies to fl.
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DISCUSSION
The role of bacterial infections in the pathogenesis of reactive arthritis is widely
accepted and suggested in other seronegative spondylarthropathies (14-16). It is
as yet unclear whether the arthritis-inducing potential of microorganisms repre-
sents the sequelae of a persisting infection or the induction of a pathologic
immune response (17). The strong association of the various types of spondylar-
thropathies with HLA-B27 supports the idea that the immune reactivity of the
host plays a crucial role.
Recently fl. frw/gdor/m has been added to the list of microorganisms that
have been identified as disease inducing infectious agents preceding the sudden
onset of reactive arthritis or Reiter's syndrome (3). Nine patients who presented
with reactive arthritis were found to have antibodies to fl. ÖHrgiior/en. Alto-
gether 6 of them had sacroiliitis. The clinical descriptions of these patients, as
well as the high prevalence of HLA-B27 in this group, support the clinical
diagnoses of Reiter's syndrome rather than Lyme borreliosis (4). The diagnosis
of chronic fl. OMrgdor/en infection was strengthened by the demonstration of
specific T-cell reactivity. All patients were treated with doxycycline. Although
antibody titers decreased significantly, only 1 patient had a complete remission
after antibiotic treatment.
Based upon these findings, we asked whether B. bwrgiior/èn may play a role
in the etiology of ankylosing spondylitis, as has been suggested in the literature
(3-7). In this study we found antibodies to B. burgdor/m' in 8.8% of patients
with AS. Clinically, these patients were thought to have definite AS and no
Lyme borreliosis. All these patients had negative Western blot patterns. Lym-
phoproliferative responses to B. burg^or/en were not performed in these
patients, because elevated responses also occur frequently in healthy controls
(18). No clear difference in the prevalence of positive Lyme serology among
B27+ and B27- patients with AS was found. Positive Lyme serology in patients
with AS is insufficient evidence to hold fi. OMrgdor/m responsible for AS.
An unexpected (and unexplained) finding was the higher prevalence of
antibodies to fi. £>Hrgcfo//m among controls than among patients. The percent-
age seropositivity among the controls, however, is quite comparable to the
findings in a group of blood donors from the same geographic area (17%) (10).
The reason for the lower sero-prevalence among the patients remains unclear.
The area from which the patients, controls and blood donors were recruited is
situated near the Dutch North sea coast which has an extensive range of dunes.
Ticks from this region are known to be infected with fi. ÖMrgdor/m (19). Due
to the limitations caused by their disease, patients with AS may have had lower
exposure to infected ticks, although they reported to spend on average 3,5 h
outdoors every day during the summer period. We have not assessed, however,
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how many of these hours have been spent in tick infected areas such as the
coastal dunes.
In conclusion, we have found positive Lyme serology in 8.8% of Dutch
patients with AS. Clinical manifestations of Lyme borreliosis did not occur in
these patients. We do not feel these patients with AS have chronic Lyme
borreliosis infection. Positive test results of Lyme serology should be carefully
interpreted in populations with a low prevalence of Lyme disease (20,21).
Reactive arthritis and AS both belong to the spondylarthropathies. However,
based on our study, the suggestion that fi. öwrgdor/ien' triggers a reactive arthritis
in genetically susceptible hosts can not be extended to patients with AS.
The assistance of C Bakker, C Braakman, A Hidding, C Jonker and A Mackaay-
Kluck is greatly acknowledged.
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Diagnostic tools in Lyme borreliosis:
clinical history compared with
serology. '
ABSTRACT
The occurrence of a history of clinical Lyme borreliosis and the prevalence of
positive antibodies to Borre/za ÖMrgdor/èn' were studied in 431 Dutch hunters.
The majority of the hunters (336 or 78%) did not report any complaints and had
no positive IgG antibodies to fiorre//a öurgdor/m'. Sixty-five hunters (15.1%)
had no clinical manifestations but did have positive antibodies to fio/re/z'a
£w/-gdor/i?n. Only 1.9% of the population studied had had past symptoms of
definite or probable Lyme borreliosis.
Likelihood ratios were high (21.3) for the recognition of erythema migrans,
but much lower for tick bites (3.6) or positive IgG Lyme serology (3.5). Clinical
history turned out to be a more powerful diagnostic tool than Lyme serology.
INTRODUCTION
Lyme borreliosis is a multi-system disease that can affect the skin, heart, nervous
system and joints (1). Since the culture or direct visualization of fiorre/za
fturgrfor/en (fi. bMrgdor/m,) from patient specimens is difficult, serology is
currently considered to be the only practical laboratory aid in establishing a
diagnosis (1). However, serologic results have to be interpreted with caution; the
physician has to be aware of both false negative and false positive results and of
interlaboratory variation (2,3,4). In addition, a large number of people have
asymptomatic B. bwrgdor/m infections. For instance, positive Lyme serology
is quite common in Swiss orienteers, but the clinical disease itself occurs
infrequently (5).
It is therefore necessary to gain knowledge about the ratio of apparent-to-in-
apparent infections and prevalence of the clinical disease in populations, where
the serologic test is applied.
We were able to study the prevalence of positive Lyme serology and the past
occurrence of clinical Lyme borreliosis in a population at risk (hunters). A
clinical and serological follow-up was done among hunters, who either reported
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signs or symptoms suggestive of Lyme borreliosis, or had positive IgG Lyme
serology.
We also assessed the clinical usefulness of several diagnostic tools by calcu-
lating likelihood ratios for (1) the recognition of erythema migrans (photographs
of this skin condition were shown), (2) a history of tick bites, and (3) positive
IgG Lyme serology. :
PATIENTS AND METHODS
Dutch hunters, members of the Koninklijke Nederlandse Jagers Vereniging
(Royal Dutch Hunting Society) living all over the country, were invited to
participate in the study. Prior to the hunting season, they meet at different
locations in the Netherlands to hold dog trials. The hunters were asked to
participate in the study at one of these places. The board of the Hunting Society
encouraged their participation.
In the Netherlands the infection rate of /jcoctes r/c/nw.s with fi.
ranges from 2.4 to 14.3% (6).
Study population
Four pictures of erythema migrans in different stages of development were
shown to all participating hunters. They were asked to complete a questionnaire
on site, which dealt with exposure to ticks and possible manifestations of Lyme
borreliosis. Specific questions were asked about tick bites, meningitis, facial
palsy, rhythm disturbances and arthritis. Participants were encouraged to discuss
problems associated with the questionnaire, or any questions they might have
regarding the erythema migrans pictures with the investigators. After the ques-
tionnaire was completed, 10 ml of blood was obtained by venipuncture to
determine the presence of IgG antibodies to 5. bwrgJor/i?n.
If the answers given in the questionnaire suggested Lyme borreliosis, e.g.
redness of the skin, cardiac, neurologic or joint symptoms, further information
from the participants was obtained by telephone.
If, after completion of the questionnaire and the telephone interview, the
history of the participants still suggested Lyme borreliosis, aprofrab/e diagnosis
of clinical Lyme borreliosis was made in cases where the hunter had not
consulted a physician. A tfe/ï/i/fó diagnosis of Lyme borreliosis was only made
if it was confirmed by a physician. After this part of the study had been
completed, all participants received a letter about the findings of the study. The
letter included the participant's individual results. A copy for the general
practitioner (GP) was enclosed.
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Hunters, who had a probable or definite diagnosis of Lyme borreliosis,
positive serology, or who had ambiguous symptoms, were invited to participate
in a 6-month follow-up study. The purpose of this follow-up study was (1) to
detect a delayed increase in the optical density value of serum in hunters with
ambiguous symptoms, and (2) to evaluate development of possible clinical
Lyme manifestations in hunters with positive serology who did not have any
symptoms in the first study. In this, the second part of the study, pictures of
erythema migrans were sent to the selection of hunters mentioned above to-
gether with a second questionnaire, which again contained questions about
clinical manifestations of Lyme borreliosis. These included tick bites, meningi-
tis, facial palsy, rhythm disturbances and arthritis. In addition, names and
addresses of their physicians were asked for. A second blood sample was
obtained through their GPs. This specimen was sent to our laboratory. The same
rules for the definition of definite or probable disease were applied in both parts
of the study. When interpretation of reported symptoms remained unclear, a
letter was sent to the patient's GP or any other physician consulted. This was
done after obtaining informed consent. We asked specifically for findings that
might help in establishing a definite diagnosis of clinical Lyme borreliosis.
Serology
Blood samples from all participants were tested for B. Zwrgdor/en' specific IgG
antibodies, by an enzyme linked immunosorbent assay as described elsewhere
(7,8). An optical density value of 0.35 was taken as the cutoff point. This value
was 2 SD above the mean value of 128 sera based on Dutch healthy laboratory
staff members (9). The intra and intertest precision were 94% and 91% at this
cutoff point. Setting the cutoff point at 0.35, meant that the sensitivity of the
serologic test varied from 40% to 96% depending on the clinical manifestations
in cases of definite Lyme borreliosis: early Lyme borreliosis, 40% (n = 25); and
late Lyme borreliosis, 96% (n = 27).
Likelihood ratios
Likelihood ratios (percentage true positive : percentage false positive) were
calculated for (1) the recognition of erythema migrans, (2) a history of tick bites,
and (3) the presence of IgG antibodies to #. ÖMrgdor/i?/-/ (likelihood ratio of the
positive test) (10). Data from two other recent studies were included in the
calculation of these likelihood ratios (11,12). Using larger numbers narrows the
confidence interval for the likelihood ratio estimate (10). We feel that it was
justified to pool the data of the three studies, because the same pictures of
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erythema migrans were shown. The same questions about clinical manifesta-
tions of Lyme borreliosis were asked and antibodies to B. burgt/or/ên were
determined in the same laboratory. However, the participants in these three
studies were probably not homogeneous concerning their rate of exposure.
Approximate 95% confidence intervals for the likelihood ratios were calcu-
lated. Confidence intervals for sensitivity, based on the binomial distribution,
were divided by 100%-specificity.
RESULTS
Prevalence of clinical and serological Lyme borreliosis
August through October 1989, serum samples were obtained from 431 hunters
(35% of the eligible study sample) who were all interviewed. Altogether, 289
(67%) were male and 142 (33%) were female. The mean age of the 431 hunters
was 40.5 years (ranging from 10 to 76).
The majority of the hunters (336 or 78%) did not report any complaints, had
not suffered from erythema migrans as shown on the pictures provided them,
and had no positive antibodies to fl. b«rgdor/i?n' (Table 1).
Five seropositive hunters reported clinical symptoms. One hunter had
suffered from arthritis (confirmed by his GP). This case was definitely diag-
nosed as Lyme borreliosis. Four hunters recognized erythema migrans from the
pictures shown. However, in these hunters erythema migrans was not confirmed
Table 1. Definite and probable Lyme borreliosis in Dutch hunters related to the results of
ELISA antibody tests.
Antibodies to Bo/re/ia fcurgdor/en
Positive Negative Total
Reported Clinical
Symptoms
Yes Definite
Probable
No Lyme
1
4
3 4
4
22 22
No 65 336 401
Total 70 361 431
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by their physicians. Therefore, a probable diagnosis of Lyme borreliosis was
made in these 4 cases.
Twenty-five hunters reported clinical symptoms, but did not have positive
antibodies to B. OMrgdor/m. Three of the 25 hunters had erythema migrans
confirmed by their physicians. In these 3 cases a definite diagnosis of Lyme
borreliosis was made (Table 1). They had been treated with antibiotics early in
their disease course. Thirteen of the remaining 22 hunters reported recognizing
erythema migrans from the pictures. However, the diagnosis of erythema mi-
grans could not be confirmed by their physicians, who either never saw a rash,
or saw a rash and did not feel it was erythema migrans. Four hunters had
experienced musculoskeletal symptoms, two had had unclear cardiac symptoms
in the past, and three had had neurological symptoms. This group of 22 hunters
was not felt to have had clinical Lyme borreliosis on the basis of the answers
given in the interview by telephone.
Sixty-five of the 431 hunters did not have any complaints, but had positive
antibodies to B. bwrgc/or/en. This meant that 15.1% of the hunters were asymp-
tomatic seropositive.
Four seropositive hunters had/j/oftaft/e clinical Lyme borreliosis (erythema
migrans in all 4), whereas 4 others (1 seropositive and 3 seronegative) had
cfe/m/te clinical Lyme borreliosis (erythema migrans in 3, arthritis in 1). The
total prevalence for probable and definite clinical Lyme borreliosis was 8/431
or 1.9%.
Altogether, 358 (336 + 22) hunters (or 83%) were seronegative and did not
have clinical manifestations, which supported a diagnosis of Lyme borreliosis
(Table 1).
Among those who must have been exposed to B. ÖMrgrfor/èn (i.e. those who
had clinical Lyme disease or are still seropositive), there was a significant
relationship between the recall of tick bites and the presence of clinical features
of Lyme borreliosis. The 8 hunters with probable or definite Lyme borreliosis
all recalled tick bites. 33.8% of the 65 asymptomatic seropositive hunters
remembered at least one tick bite (Fisher Exact p<0.001). However, there were
no significant differences between the last group and the 358 seronegative
hunters without Lyme borreliosis, of whom 31.8% remembered a tick bite (X^
0.10-NS).
Follow-up study
The 95 hunters (or 22% of the whole group), who had reported clinical manife-
stations of Lyme borreliosis or showed positive Lyme serology, were invited to
take part in the follow up study. Surveys and serum samples were received from
66 hunters (69.5%) (Table 2).
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Table 2. ELISA IgG antibodies to florre//a ftj/rgdor/en' in Dutch hunters in the autumn of
1989 compared with the presence of antibodies in the spring of 1990.
IgG antibodies
Spring
Positive
Negative
Total
IgG antibodies Autumn
Positive
30
20
50
Negative
1
15
16
Total
31
35
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The only hunter with definite Lyme borreliosis and positive antibodies also
remained seropositive. He had been successfully treated for his arthritis with a
course of oral doxycycline.
The optical density values of 3 out of the 4 hunters with probable Lyme
borreliosis and positive antibodies to 5. &Mrgdor/èn remained positive. One
hunter did not respond at follow-up.
The 3 hunters with physician confirmed erythema mi grans without antibodies
remained seronegative. One of them developed secondary red annular lesions
and was retreated with doxycycline.
Seven seronegative hunters, who reported recognizing erythema migrans
during the first study, also took part in the follow-up study. They all remained
seronegative. Three of the hunters with musculoskeletal complaints responded
as well. They remained seronegative as did one of the hunters with unclear
cardiac symptoms. By contrast, one of the hunters with neurologic complaints
had become seropositive by the time the follow up was carried out. His optical
density value had increased moderately from 0.27 to 0.39. Unfortunately, he did
not give permission to obtain information from his physicians. One other hunter
with neurological complaints remained seronegative, while a third one did not
respond.
Altogether, 26 hunters remained asymptomatic seropositive without any
change in their IgG anti-Borrelia antibodies. Twenty hunters, who were asymp-
tomatic seropositive, became seronegative during the follow-up period.
Therefore, we may conclude the follow-up study among the 66 hunters did
not reveal any new cases of Lyme borreliosis.
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Use of diagnostic tools
In the present study, 20 hunters (4.6%) said they recognized erythema migrans
from the pictures shown them. In 3 out of the 20 cases a definite diagnosis of
Lyme borreliosis was made. Twenty-one out of 362 patients and controls in the
two earlier studies said they recognized erythema migrans from the pictures
(11,12). In 1 patient a definite diagnosis of Lyme borreliosis could be made.
Combining the results of these three studies, 41 of 793 (5.2%) individuals
believed they had had erythema migrans at some time. In 4 cases a definite
diagnosis of clinical Lyme borreliosis was made. This implies that for definite
clinical Lyme borreliosis the positive predictive value equals 4/41 (or 9.8%).
The positive predictive value covers all individuals with a positive test result
(recognition of erythema migrans) who definitely have the disease. Although
Table 3. Likelihood ratio for erythema migrans confirmed by physician (pooled data).
Erythema migrans, physician confirmed
Erythema migrans
recognized from
pictures
yes
no
yes
4
0
4
no
37
752
789
total
41
752
793
Likelihood ratio: Positive test (LR+)=(4:4):(37:789)=21.3 (95% Confidence Interval 8.5,
21.3)
Table 4. Likelihood ratio for recalled tick bites (pooled data).
Lyme borreliosis
present absent total
Tick bite yes 4 174 78
no 1 614 615
5 788 793
Likelihood ratio: Positive test (LR+)=(4:5):(174:788)=3.6 (95% Confidence Interval 1.3,
4.5)
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Table 5. Likelihood ratio for positive Lyme serology (pooled data).
Lyme borreliosis
Antibodies to
Zto/re/ia èurgdoz/m'
yes
no
present
2
3
5
absent
90
698
788
total
92
701
793
Likelihood ratio: Positive test (LR+)=(2:5):(90:788)=3.5 (95% Confidence Interval 0.5,7.5)
this may seem rather low, it is still higher than the positive predictive value for
the presence of IgG antibodies to B. ö«rgrfor/<?r/. Only 1 of the 70 seropositive
hunters in the present study had definite clinical Lyme disease (Table 1), which
accounts for a positive predictive value of only 1.4%.
Based upon the pooled data from the three studies, we calculated a likelihood
ratio of 21.3 for the recognition of erythema migrans (Table 3) (10). By contrast,
the diagnostic-discriminative value of the tick bites recalled as part of the
clinical history, is much lower with a likelihood ratio of only 3.6 (Table 4). The
likelihood ratio for the presence of positive antibodies to B. ÖMrgdor/èn was 3.5
(Table 5). (We only calculated likelihood ratios for past erythema migrans, tick
bites and positive antibodies to B. e«rgrfor/en', since these features are the
hallmarks of Lyme borreliosis, whereas none of the participants in our studies
had had Bannwarth syndrome or atrio-ventricular block. Therefore, we were not
able to calculate likelihood ratios for these less frequent Lyme disease manifes-
tations).
These likelihood ratios were applied in a nomogram adapted from Fagan
(figure 1-4) (13). In the normal Dutch population the pretest probability for
Lyme borreliosis is low, being about 0.1%. For someone who remembers a tick
bite, the posttest probability of having Lyme borreliosis is 0.3% (figure 1). If a
person recognizes erythema migrans from pictures, his posttest probability is
2%. If somebody has antibodies to B. èwrgdor/i?/-/ the posttest probability is
0.3%. When two of these features occur together the maximum posttest prob-
ability is 5% (assuming independence). When three variables are combined the
posttest probability may reach 15% (figure 2).
In a population with a higher pretest probability, such as that of the hunters in
this study (nearly 2%), the posttest probability was considerably higher: recog-
nition of erythema migrans yields a posttest probability of as much as 30%
(figure 3). When the three variables are combined (recognition of erythema
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migrans, history of a tick bite and IgG antibodies to fl. èwrgrfor/en), the posttest
probability is nearly 75% (assuming independence) (figure 4).
DISCUSSION
Our study confirms another study which concluded that hunting is associated
with an increased risk of developing seropositivity for Lyme borreliosis (14). In
control populations of healthy Dutch blood donors, we found only 9% seroposi-
tivity (9). We detected only 4 cases of definite and 4 cases of probable clinical
Lyme borreliosis (total prevalence 1.9%) among 431 Dutch hunters (14). Since
seronegative hunters, who did not report complaints, were not retested after 6
months, we were not able to estimate the /«c/(ie«ce of seropositivity and clinical
Lyme borreliosis for Dutch people at risk (hunters). In a Swiss study the annual
incidence for clinical Lyme borreliosis was estimated at 1.6% for a population
at risk (orienteers) (5).
In the present study, 15.1% of the hunters showed positive antibodies to fl.
£>M/-g<io/-/(?/7, but they did not report signs or symptoms attributable to Lyme
borreliosis. Similar findings have been reported in a number of studies
(15,16,17). There is one study, however, which reports that 11 out of 12 farmers
with antibodies had Lyme borreliosis (18). Generally, in the European countries,
the risk of developing Lyme borreliosis given exposure would appear to be
rather low.
It is not unusual that the clinical diagnosis of Lyme disease may be difficult
to establish. Only approximately 50% of patients develop erythema migrans (1).
Quite often Lyme borreliosis patients present fairly with late with manifestations
in the nervous, cardiac, or musculoskeletal systems. For those patients who had
erythema migrans in the past, it might be difficult to reliably elicit this sign from
the patient's history. Based upon the results of the present study, we think it is
worthwhile to show photographs of different stages of erythema migrans to
patients, in whom a diagnosis of Lyme disease is considered. However, a few
caveats regarding the use of pictures of erythema migrans as a diagnostic tool
should be mentioned. Only pictures of erythema migrans were shown in our
study. No other pictures of red annular skin lesions were included in the series.
This may imply that erythema migrans may tend to be overdiagnosed, limiting
the predictive value of this test. We used confirmation of erythema migrans by
a physician (and not serologic results) as the "gold standard" for a definite
diagnosis of Lyme borreliosis. A specific antibody response to fi. b«rg<i0r/i?n'
may be suppressed early in Lyme disease and antibiotic treatment may abort
specific antibody responses (19). Since the majority of the participants, who
reported to have had erythema migrans in the past, did not have physician-con-
firmed erythema migrans, were not treated with antibiotics, and did not have
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antibodies to fl. Z>«rg<ior/i?n, recognition of erythema migrans from photographs
almost certainly results in an overestimation of the true prevalence of this skin
lesion. Nonetheless, we think that showing typical pictures of erythema migrans
can be a useful tool in epidemiological studies. This applies to the clinical setting
too, if one is aware of this bias, i.e. the tendency to overreport.
Another important issue is the setting in which a diagnostic test is performed:
the strong influence of the prevalence (pretest probability) on the usefulness of
a test. In a population, such as the Dutch population, with a low prevalence of
Lyme borreliosis and a high prevalence of positive Lyme serology, diagnostic
testing is of limited value as is easily shown when likelihood ratios are applied
in the nomogram. These figures clearly show that the pretest probability has an
overriding influence on the discriminative power of a test. The posttest prob-
ability for a person with a high degree of exposure (hunter) is much higher than
for a person from the general population (figures 1-4). Only when the presence
of three variables (erythema migrans, tick bite, positive Lyme serology) is
applied sequentially, a considerable posttest probability can be reached. Theo-
retically, as several diagnostic tests are combined sequentially, there is a risk of
creating a distorted posttest probability at the end of the sequence (10). The
posttest probability will be overestimated, because the combined tests are not
independent. This is, however, not often a major problem with relatively short
series of 2 or 3 diagnostic tests (10).
The application of likelihood ratios clearly illustrates, that a clinical history
of erythema migrans has more impact on the diagnosis of Lyme borreliosis than
simply testing for antibodies to fi. öurgdorfen. This strengthens the view that
the diagnosis of Lyme borreliosis should be based on clinical symptoms (20).
The presence of antibodies to fl. öurgtfor/en' is enough to reinforce the clinical
diagnosis. Lyme serology should not be used in any form of screening for Lyme
disease.
In summary, only 1.9% of the studied population at risk had past symptoms
of definite or probable Lyme borreliosis and 15.1% had antibodies to fl. bwrg-
dor/èn' without any clinical symptoms. In Lyme borreliosis, as in many other
diseases, the clinical history is a very powerful (and cost-effective) diagnostic
tool. It is important to have a reliable estimate of the pretest probability of Lyme
borreliosis, in the setting in which these diagnostic tests are done.
We thank all the participating members of the Koninklijke Nederlandse Jagers
Vereniging for their enthusiastic cooperation.
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Rational diagnosis and treatment in
unclassified arthritis:
how clinical data may guide requests
for Lyme serology and antibiotic
treatment.
ABSTRACT
In order to improve the appropriateness and efficiency of diagnostic serologic
tests and subsequent antibiotic treatment, clinical data of 102 patients with
unclassified arthritis were analysed, to investigate whether the presence of
positive IgG antibodies to fiorre/ia bwrg<i0//<?n could be predicted.
The clinical data were blindly ranked from 1 to 4 (1, Lyme arthritis unlikely;
4, Lyme arthritis very likely). Antibodies to fi ÖMrgdor/èn were positive in 9 of
102 patients (9%). Six of 15 (40%) patients with rank numbers 3 and 4 were
positive for antibodies to fl b«rgdor/i?n, in contrast with only three of 87 (3%)
patients with rank numbers 1 and 2.
The likelihood ratio of positive Lyme serology for patients ranked 3 and 4 was
12.0, for patients ranked 2 to 4, 4.5, and for patients with arthritis of the knee,
3.0. These likelihood ratios were associated with a post-test probability of 55%,
30%, and 20% respectively.
The clinical history in patients with unclassified arthritis can largely predict
the presence of antibodies to B burg^or/en'. The absolute value of a likelihood
ratio can be a contributing factor in deciding to request antibodies to fi
n in patients with unclassified arthritis.
INTRODUCTION
In Lyme borreliosis, a disorder caused by the tick borne spirochete
ö«rgrfo//<?n, the musculoskeletal system is often affected (1). Common symp-
toms of this disease are migratory pain in joints, tendons and bursae, brief
arthritis attacks, and in later stages prolonged arthritis attacks, chronic arthritis
and peripheral enthesopathy (2). The musculoskeletal symptoms may occur
without preceding erythema migrans, cardiac or neurologic symptoms (1).
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Lyme arthritis, though not a common cause of arthritis (at least not in the
Netherlands), should be considered in the differential diagnosis because antibi-
otic therapy is usually effective (3-5). Owing to a large number of false positive
results, and other reasons including economic aspects, however, it seems inap-
propriate to test for antibodies to fl ÖMrgdor/m in all patients with unclassified
arthritis (6). It is important to know in which subset of patients with arthritis the
test should preferably be ordered to obtain clinically meaningful results.
The presence of characteristic signs or symptoms of Lyme borreliosis in the
clinical history and physical examination of patients with arthritis should guide
rheumatologists in the decision to request antibodies to fl öurgrfor/èr/.
The purpose of the present study was to investigate how we could estimate
the presence of antibodies to fi èwrgiior/èn' from clinical data in patients with
arthritis, and how this influences the decision to prescribe antibiotic treatment.
PATIENTS AND METHODS
Antibodies to fi frurgdor/m were determined in all patients with arthritis from
the outpatient department of rheumatology of the University Hospital of Leiden
—that is, those patients in whom a firm rheumatic diagnosis could not be made
on their first visit or after several visits. Specifically, these patients did not fulfill
criteria for rheumatoid arthritis, osteoarthritis, gout, systemic lupus erythema-
todes, chondrocalcinosis, reactive arthritis or seronegative spondylarthropathy.
Based only on the clinical history and physical examination of the individual
patient, all patients were given a rank number from 1 to 4, where 1 is considered
unlikely and 4 very likely to be Lyme arthritis. The criteria for these rank
numbers were set for this particular study (table 1). These criteria were based on
published work about the natural history and our own experience of patients with
Lyme arthritis (2,5,7,8). The surveillance case definition for Lyme disease as
developed by the Centers for Disease Control in the United States, was also
incorporated (9). Patients were given a rank number without knowledge of the
serological results. We expected positive serologic results mainly in patients
ranked 2 to 4. Seronegativity was not expected among patients with arthritis due
to Lyme borreliosis, which is a late stage of Lyme disease (1,2,7).
Serology
IgG antibodies to fl b«/-,gdo//<?n were determined by an enzyme linked immu-
nosorbent assay (ELISA) as described elsewhere by the National Institute of
Public Health and Environmental Protection (Bilthoven, the Netherlands)
(10,11). The ELISA values are expressed as optical density ratios. An optical
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Table 1. Criteria for ranking patients with arthritis (arthritis with or without a history of an
erythematous skin lesion, tick bite, neurological, or cardiac disorders) at their probability of
Lyme borreliosis. Ranking based on the clinical history and physical examination of the
individual patient
Rank
4
3
2
1
Definition
Very likely to be
Lyme arthritis
Likely to be
Lyme arthritis
May be
Lyme arthritis
Unlikely to be
Lyme arthritis
Condition
Erythematous skin lesion or ACA* and
tick bite;
erythematous skin lesion or ACA and neurological disorders''"'"
erythematous skin lesion or ACA and cardiac disorders''"'"'';
tick bite and neurological disorders;
tick bite and cardiac disorders;
neurological and cardiac disorders.
Erythematous skin lesion;
tick bite;
neurological disorders;
cardiac disorders;
ACA;
or recurrent arthritis of the knee.
Arthritis of the knee.
Mono or oligo arthritis of other joints;
polyarthritis
* ACA= Acrodermatitis Chronica Atrophicans; ++ For example, facial palsy, Bannwarth's
syndrome; +++ For example, atrioventricular conduction defects.
density ratio of two is three standard deviations above the mean of 35 serum
samples from blood donors. An optical density ratio equal to or greater than two
is considered positive. If a positive test result was obtained the TVe-pone/na
pa//ktom haemagglutination assay was performed to exclude false positivity due
to antibodies to 7pa///dMm. Serum samples from this institute were also tested
at the laboratory of the department of microbiology of the University of Limburg
at Maastricht, the Netherlands (Dr MKE Nohlmans) in accordance with a Dutch
Lyme study group. There was good agreement between laboratories (r=0.94;
p<0.001) (unpublished results). In the absence of a reference or "gold" standard,
an exchange of serum samples between the department of microbiology at
Maastricht and the department of zoology, University of Neuchatel, Switzerland
(Dr L Gern), resulted in good agreement between the two laboratories (r=0.68;
p=0.001)(12).
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Diagnostic tools
Sensitivity, specificity, positive predictive values and likelihood ratios (percent-
age true positive: percentage false positive) were calculated for patients in ranks
3 and 4, ranks 2 to 4, and for all patients who presented with arthritis of the knee
(13).
Statistical analysis
For categorical data the X^ test was used to test for significant differences
between proportions. A value of p < 0.05 was considered statistically significant.
RESULTS
From January 1989 to April 1991 IgG antibodies to ZJ Z>Mrgdor/<?n were deter-
mined in 102 patients with unclassified arthritis. The mean age of these patients
was 42.8 years (ranging from 14 to 75 years). The male to female ratio was 1.1:
1.0.
Table 2 gives rank numbers and the proportion of patients positive for
antibodies to fl owrg^or/en'. Nine patients were positive for antibodies to fl
öurgdor/en (9%). Table 3 gives the clinical symptoms of the 15 patients with
rank numbers 3 and 4. Six of these 15 patients (40%), were positive for
antibodies to B öwrgdor/èn. Eight of these 15 patients had recurrent arthritis of
the knee, whereas two were positive for antibodies to fl £>Mrg<ior/i?n' (25%) (table
3). Of the 30 patients with non-recurrent arthritis of the knee and ranked 2, only
Table 2. Rank numbers of 102 patients and the proportion of patients positive for antibodies
to Borre/ia /wgdor/èn' within each category
No (%) of patients with positive IgG serology
Rank 4
Rank 3
Rank 2
Rank 1
(n= 2)
(n=13)
(n=30)
(n=57)
2 (100)
4 ( 31)
1 ( 3)
2 ( 4)
Total 102 9 ( 9 )
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Table 3. Clinical symptoms and antibodies to florre/ia fcwrgdo
4.
f patients ranked 3 and
Patient Clinical symptoms Rank Antibodies
1 1986 tick bite
1988 severe stiff neck
1989 severe stiff neck
1986-1990 arthralgia
1990 frank arthritis of the knee and ankle
2 1989 tick bite with erythematous skin lesion
1990 arthritis of the knee
3 1990 facial palsy and polyarthritis
4 1989 bite, pericarditis and recurrent arthritis
5 1985 erythema migrans (confirmed by doctor)
1986 arthritis of the knee
1990 arthritis of the knee
6 1988 facial palsy and arthritis of the ankle
1990 arthritis of the ankle
7 1991 polyarthritis and acrodermatitis chronica atrophicans
8 1990 tick bite and arthritis of the knee
9 1987 tick bite
1989 recurrent arthritis of the knee
10 1987-89 recurrent arthritis of the knee
11 1987-90 recurrent arthritis of the knee
12 1988-89 recurrent arthritis of the knee
13 1987-90 recurrent arthritis of the knee
14 1989 recurrent arthritis of the knee
15 1986-89 recurrent arthritis of the knee
Positive
Positive
Negative
Negative
Negative
3
3
3
3
3
3
3
3
3
3
Negative
Positive
Positive
Positive
Negative
Negative
Positive
Negative
Negative
Negative
one (3%) was positive for antibodies to B burg^or/en. The two patients ranked
1 (4%), who were positive for antibodies to fi bwrgdor/m had symmetrical
polyarthritis and arthritis of the metatarsal joints of one foot.
Patients with rank numbers 3 and 4 were positive for antibodies to fi ftwrg-
dor/m significantly more often than patients with rank numbers 1 and 2
(p<0.001). Patients with recurrent arthritis of the knee were positive for antibo-
dies to B bwrgrfor/èn significantly more often than patients who had their first
attack of arthritis of the knee (p<0.05).
The sensitivity was moderate for patients ranked 3 and 4 (40%) (table 4). The
positive predictive value was 66%.
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Table 4. Sensitivities, specificities, positive predictive values, and likelihood ratios of
clinical evidence as a diagnostic test for Lyme arthritis at different levels of clinical suspicion
of disease. Positive Lyme serology among 102 patients with unclassified arthritis is taken as
the gold standard for the disease
Positive
serology
Sensitivity
(%)
Specificity
(%)
Positive
Predictive
Value
Likelihood
ratio
Ranks 3 and 4 (n= 15)
Rank 2,3, and 4 (n=45)
Arthritis of the knee (n=41)
6
7
6
40
15
14
96
96
95
66
77
66
12.0
4.5
3.0
The likelihood ratios calculated for each cutoff level were applied in a
nomogram adapted from Fagan (14). The pretest probability for positive Lyme
serology in this group (patients with unclassified arthritis) was 9% (table 2). If
Lyme serology was requested for patients with rank number 3 or 4, the posttest
probability to have Lyme borreliosis increased to nearly 55%. If patients with
arthritis of the knee (rank 2) are added to this group, the posttest probability
decreased to 30% (figure 1).
Knees are the most affected joints in Lyme borreliosis (2,5,7). Therefore we
placed all the patients with a first attack of arthritis of the knee and with recurrent
arthritis of the knee in one group (41 patients from rank 2 to 4). After this we
calculated the sensitivity (14%), the specificity (95%), the positive predictive
value (66%) and the likelihood ratio (3.0) (table 4). This likelihood ratio was
associated with a posttest probability of Lyme borreliosis of 20% (figure 1).
As only nine of the 102 patients with unclassified arthritis had positive Lyme
serology, the serologic test can be regarded as unnecessary in 93 patients (91 %).
If antibodies to B bw/gdo/ƒ<?/•/ had been determined in the 15 patients with rank
numbers 3 and 4 only, the test would have been unnecessarily ordered in only
nine patients. This implies that the number of requested tests for antibodies to fi
OMrgcfor/er/ would be decreased from 102 to 15—that is, a decrease of 86%. This
would have been at the expense of the three patients with rank numbers 1 and 2,
who were also positive for antibodies to £ ö«rgrfor/(?r/ (table 2). These three
patients are clinically believed to have a low probability of Lyme arthritis.
Antibodies to fl burgdoz/en were determined in 41 patients with arthritis of
the knee: six were positive for these antibodies. Therefore the test was unneces-
sarily ordered in 35 patients (85%). Five of six patients with arthritis of the knee
and positive antibodies to fi frurgcior/m were placed in ranks 3 and 4. If requests
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Figure 1: Posttest probability of Lyme ar-
thritis at different cutoff levels in patients with
unclassified arthritis after application of likeli-
hood ratios (pretest probability 9%). Likeli-
hood ratio Ranks 3 and 4,12.0 ( ); Likeli-
hood ratio Ranks 2-4,4.5 ( . . .) ; Likelihood
ratio for arthritis of the knee, (3.0) ( ).
(Reprinted, by permission of the New Eng-
land Journal of Medicine 1975;293:257.)
for antibodies to fl frwrgdor/<?n had been made for patients with arthritis of the
knee with rank numbers 3 and 4, requests could have been decreased from 41 to
five tests (88%) at the expense of one patient with rank number 2.
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DISCUSSION
This study indicates that signs and symptoms of the clinical history of a patient
with arthritis are important tools to predict the chances of a positive test for
antibodies to £ fewrgdor/m. Patients who clinically were expected to have a high
probability of positive antibodies to £ öwrg<fo//m had a posttest probability of
Lyme borreliosis of 55% (based on serologic test results). It is often difficult to
decide at what posttest probability the diagnostic process should be stopped and
treatment should be started, and at which level a working diagnosis can be
rejected (13). In the clinical situation there is currently, no other widely available
test to increase the posttest probability of Lyme borreliosis. Culturing of the
Lyme spirochetes, especially from synovial fluid, is difficult and time consum-
ing (1,15). The clinical value of Western blotting, cell mediated immunity
testing, urine antigen testing, and the polymerase chain reaction still have to be
determined. In the meantime, it is up to the clinician to decide whether a posttest
probability of a disease of, say, 50%, is sufficiently supportive to start treatment
in a patient with arthritis. If the clinical history in a patient with arthritis is likely
to be Lyme borreliosis (in our study patients with rank numbers 3 and 4), the
chances of having Lyme borreliosis are about 55%. This degree of suspicion is
probably high enough to justify starting antibiotic treatment in a patient with
arthritis, especially because first choice treatment with doxycycline by mouth is
rather simple and usually has only minor side effects (4).
Determination of antibodies to £ è«rg<ior/èr/, in patients with unclassified
arthritis, can only be considered useful when it has direct therapeutic con-
sequences—that is, subsequent antibiotic treatment. Four different strategies
will now be discussed: (a) all patients with unclassified arthritis are to receive
antibiotic treatment, serologic tests are not needed; (b) only patients with a high
suspicion of Lyme borreliosis (rank numbers 3 and 4) are to receive antibiotic
treatment, serologic tests are not needed; (c) antibodies to £ ÖHrgdor/en are
requested for all patients with unclassified arthritis and, subsequently, the
patients positive for antibodies to £ ö«/-g<io//m are treated with antibiotics; and
(d) antibodies to £ bwrgdor/en are requested only for patients with rank numbers
3 and 4 and, subsequently, the patients positive for antibodies to £ frurgdor/èn
are treated with antibiotics. These four strategies have immediate consequences
for the appropriateness of treatment with antibiotics and for the request of tests
for antibodies to £ ÖHrgdor/èn, as is shown in table 5. Strategy (a) leads to the
unnecessary antibiotic treatment of 93 patients (91%). Strategy (b) decreases
antibiotic treatment to 15 patients, but leads to unnecessary treatment in nine
patients, and three patients from rank 1 and 2 are not diagnosed as having Lyme
arthritis and do not receive treatment with antibiotics. In strategy (c), 93 tests for
antibodies to £ ö«rg<ior/i?n' are requested unnecessarily. None of the patients
receive unnecessary antibiotic treatment. Strategy (d) leads to a decrease of
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Table 5. Sensitivities, specificities, predictive values, number of tests performed, and the
appropriateness of antibiotic treatment for four strategies in 102 patients with unclassified
arthritis. Positive Lyme serology among 102 patients with unclassified arthritis is taken as the
gold standard for the disease
Strategy (a)*
Strategy (b)
Strategy (c)
Strategy (d)
Sensitivity
(%)
100
67
100
67
Specificity
(%)
0
90
100
90
Positive
Predictive
Value (%)
9
40
100
40
Tests performed
Positive Negative
9 93
6 9
Antibiotic
Treatment
justified
Yes No
9 93
6 9**
9 0
6 0**
* See text for definition of each strategy; ** At the expense of three patients in rank 1 and 2.
serologic tests from 93 to 15. None of the patients will be treated wrongly;
however, three patients will be missed and will not receive treatment with
antibiotics. Comparing strategy (a) and (c), testing of 102 patients could have
avoided unnecessary treatment for 93 patients. Reduction of the tests performed
in strategy (d) avoids unnecessary treatment completely, but at the expense of
the three patients with rank numbers 1 and 2.
Several issues must be addressed with regard to our findings. There is no real
"gold standard" for Lyme borreliosis. Lyme borreliosis is primarily defined by
clinical evidence and serological results may only support this evidence (6,9). It
is necessary to evaluate the clinical signs and symptoms of patients who are
suspected to have Lyme disease carefully. Clinical evidence should outweigh
serological results. Therefore, it would be realized that the three patients positive
for antibodies to # öwrgdor/èn who are clinically considered to have a low
probability of Lyme arthritis (rank numbers 1 and 2), may in fact be asympto-
matic. This would be the case if they have been infected by borrelia strains at
some time in the past giving rise to the development of specific antibodies and
if their arthritis was not due to Lyme borreliosis but to another (as yet unknown)
cause. Asymptomatic infection with fl ÖHrgdor/m (positive antibodies but no
clinical disease) has been found in 3% - 20% of healthy subjects (6,16). The
prevalence of asymptomatic infection correlates roughly with the degree of
exposure (6,12). Secondly, if likelihood ratios are to be applied in clinical
practice, the doctor must have a reasonable estimate of the probability for Lyme
borreliosis in the patient. This implies that prevalence data should be available.
Prevalence data of Lyme arthritis in patients with unclassified arthritis are
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available for two different parts of the Netherlands (3). These prevalence data
can probably be extrapolated to other parts of the Netherlands. We feel that the
calculated likelihood ratios can be transported to patients with unclassified
arthritis in a setting comparable with ours. Thirdly, our intention was to point
out that clinical findings should guide the decision to select a serologic test. If
the doctor is convinced that a patient with arthritis has Lyme arthritis, the patient
should be treated appropriately, independent of the serologic test result. Unfor-
tunately, the clinical history and symptoms are not always clear and the doctor
may feel that he or she needs more support for the diagnosis. We have tried to
elucidate for which patients the serologic Lyme test should be selected to
improve the appropriateness and efficiency.
In conclusion, in patients with unclassified arthritis clinical data are high
associated with the likelihood of a positive test for antibodies to Z? ÖMrgrfor/erz.
Knowledge of the pretest probability of disease, extracting key elements from
the patient's clinical history and the physical examination, and application of
likelihood ratios, can guide the decision to request tests for antibodies to fi
bwrgdor/m for these patients. Such data may promote a rational and appropriate
diagnosis and treatment.
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Lyme disease.
Lyme borreliosis, which is caused by the tick-borne spirochete fio/re/ia
<ior/i?n (ö. ÖMrgdor/i?/-/), often begins with a characteristic skin rash, erythema
migrans, and may be followed by neurologic, cardiac, or joint abnormalities of
variable duration (1).
Erythema migrans is reported in 50-60% of the patients. In 15-20% of patients
in the United States, this is followed within several weeks to months by frank
neurologic involvement, which may be accompanied by radicular pain, pleocy-
tosis in the cerebrospinal fluid and meningitis with superimposed cranial nerve
involvement or peripheral neuropathy (2). Cardiac involvement occurs in up to
8% of patients, most commonly in the form of fluctuating atrioventricular block.
From 2 weeks to 2 years (usually six months) after the onset of the disease, often
after intermittent episodes of arthralgia or migratory musculo-skeletal pain,
nearly 80% of patients begin to have brief attacks of asymmetric, oligoarticular
arthritis, primarily in the large joints, especially of the knee (3).
Chronic arthritis, defined as a year or more of continual joint inflammation,
begins during the second or third year after the onset of the disease. In severe
cases, chronic Lyme arthritis may lead to the erosion of cartilage and bone and,
sometimes, though rarely, to permanent joint disability (3).
The pattern of joint involvement is similar in the United States and Europe,
but has been described less commonly in the European literature, probably due
to a lack of awareness in there (4,6). Acrodermatitis chronica atrophicans is a
late skin disorder of the disease which has been described primarily in Europe
(5).
PATHOGENESIS
The Lyme disease spirochete is transmitted by Ixodes ticks that are part of the
/xodes r/ciniw complex. They include /. <iamm/n/ in the northeastern and mid-
western United States, /. paci/icws in the western United States, /. r/awws in
Europe and /. persM/ca/MS in Asia. Ixodid ticks are also indigenous to Africa and
South America, but it is not clear whether Lyme borreliosis occurs on those
continents.
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Carrier rates in the ticks may vary. For ƒ. tfaffimim' ticks in the United States
infection rates vary from 10 to 35% and even to 50% on Shelter Island, New
York (7). Only 1 to 3% of /. pacj/ïcws ticks are infected (8). The range of
infection rates of /. ricinu.? in Europe varies from 2.2 to 40% (9,10). The
infection rate of adult ticks exceeds that of nymphal and larval ticks. Infection
rates of /. persM/co/MS are not exactly known, but fl. ÖMrgrfor/i?n has been
isolated from these ticks in China and Russia (11,12). Larvae and nymphs of/.
damm/m feed on at least 31 different species of mammals and 49 species of birds
(13). White-footed mice, PerowyscMS /eMco/?M.s, are a particularly important
host, but other animals such as short tailed shrews (fi/anrca brev/ca«<ia), rac-
coons (/Vocyon /oror), gray squirrels (5c/«r«5 carc/f/iens/.?), and white tailed
deer (Odoco/teMs viVg/rt/anMs) may also be parasitized by many juvenile ticks.
Birds are a natural vehicle for dispersing ticks into new areas (14). Adult ticks
are more restricted, and are known to feed on 13 species of mammals; they do
not feed on mice or birds. Deer are essential for the maintenance of dense tick
populations. All postembryonic stages also feed on humans.
The infection is usually acquired when nymphal ticks feed between May and
July, but only a minority of the patients remember the bite, probably because of
the small size of the ticks. Adult ticks transmit the disease when they feed in the
autumn. The disease affects people of all ages and both sexes.
In 1982, Burgdorfer and Barbour isolated a previously unrecognized spiro-
chete, now called B. bwrgdor/ien, from /. ifammi/iz ticks (15). The spirochete was
subsequently recovered from patients with Lyme borreliosis (5,7,16,17). The
Borrelia species are fastidious, micro-aerophilic bacteria that grow best at 33°C
in a complex, liquid medium called Barbour-Stoenner-Kelly medium (18). fl.
owrgdor/m has a length of 20 to 30 |im and a width of 0.2 to 0.3 urn, and it has
7 to 11 flagella. fl. bwrgdor/en' contains at least 30 different proteins, but the
functions of only a few of them are currently known. These include the two
major outer-surface proteins called outer surface protein A (30 to 32 kd) and
outer-surface protein B (34 to 36 kd) (19,20). The 41-kd antigen is located on
the flagellum (21). The 58- or 60-kd antigen appears to be a heat-shock protein
that is cross-reactive with an equivalent antigen in a wide range of bacteria (22).
Certain differences in morphology, outer surface proteins, plasmid and DNA
homology have been noted between American and European isolates of fl.
/ m ' (23).
THE CLINICAL EVOLUTION OF LYME ARTHRITIS
To determine the clinical evolution of Lyme arthritis, Steere conducted a
longitudinal study of 55 patients, who had not received antibiotic therapy for
erythema chronicum migrans, and followed them for a mean duration of 6 years
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(3). Of the 55 patients, 11 (20%) had no subsequent manifestations of Lyme
borreliosis. From 1 day to 8 weeks after disease onset, 10 of the patients (18%)
began to have brief episodes of joint, periarticular, or musculoskeletal pain
lasting as long as 6 years, but none developed objective joint abnormalities.
From 4 days to 2 years after disease onset, 28 (51%) had one episode or began
to have intermittent attacks of arthritis, primarily in large joints. The duration of
these episodes ranged from three days to 11.5 months, with a mean of three
months. Episodes of arthritis were often separated by months or even years of
complete remission.
The total number of these patients who continued to have recurrences de-
creased by 10% to 20% each year. Six patients (11%) developed chronic
synovitis.
PREVENTION
Humans encounter ticks in forests, transitional vegetative zones, pastures, parks,
lawns surrounding homes, brushwood and woodland areas bordering lawns, and
even in houses after domestic animals have carried ticks inside. Reducing the
incidence of tick bites is one of the first goals to attempt in preventing Lyme
arthritis. Control methods can be divided into four categories: (1) Personal
protection, (2) Biological control, (3) Environmental modification and physical
control, and (4) Chemical control (24).
PERSONAL PROTECTION
Efforts made by the individual to prevent tick bites and to locate and promptly
remove attached ticks may be the most effective measures that can be taken to
reduce the risk of contracting Lyme disease.
Repellents
Repellents applied to outer clothing, including the insides of pant cuffs and
socks, prevent tick bites. The acaricide permethin kills ticks (25). Standard
repellents that do not kill but repel ticks when impregnated into clothing include
deet, Indalone, dimethyl carbate, benzyl benzoate and M-1960. Treated clothing
may be protected for several weeks and after several washings. Other personal
measures to prevent tick bites are: taping the trouser cuffs, tucking the trousers
into footwear, wearing one-piece zippered suits, wearing light colored clothing
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which makes it easier to observe ticks and wearing clothes made of a smooth
weave rather than clothes of a coarse fabric.
Tick removal
Ticks attach to their hosts by cutting the skin with a pair of chelicerae and
inserting the toothed hypostome.
Ticks may be removed by grasping the tick as close to the skin as possible
with a pair of forceps or tweezers. An antiseptic should be applied to the skin
where the tick was attached.
Humans should inspect their bodies after they have visited tick-infested areas
and promptly remove ticks.
Avoidance of tick-infested areas
Avoiding visits to known tick-infested areas during the seasonal peak feeding of
nymphs from May to mid-July can reduce the risk of acquiring Lyme borreliosis.
BIOLOGICAL CONTROL
Efforts should be made to introduce and to establish natural enemies of ticks.
Until now, none of the known microbial pathogens and invertebrate or verte-
brate predators have been used successfully to control ticks (24).
ENVIRONMENTAL MODIFICATION AND PHYSICAL
CONTROL
Altering vegetation
Controlled burning may be useful by destroying the ticks active at the time of
burning, reducing the abundance of suitable animals, and make the habitat
inhospitable for ticks (26). Removal of trash piles and removal of bird feeders
may help to reduce the number of ticks in the immediate vicinity of the home.
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Denying ticks access to host animals
Reductions in tick numbers may be achieved by eliminating the number of
infected animals such as deer, but the killing of these animals will probably not
be widely accepted by the public (27).
CHEMICAL MODIFICATION
Acaricides are used for treating tick-infested animals. Domestic animals may be
dipped or fitted with a collar impregnated with acaricide. Nesting material
treated with an acaricide has been used.
Residual sprays
Residual application of acaricides for control of ticks may be effective and
practical when applied to relatively small areas frequented by humans, but will
be too costly when applied to larger areas.
Treatment of white footed mouse burrows
Control of subadult /. <iamm/«/ has been reported by the placement of the
acaricide permethin directly on and in the burrows of white-footed mice. Studies
have reported a marked reduction in numbers of larvae feeding on mice in
treated versus untreated areas (28).
PREVENTION OF LYME ARTHRITIS
There are no data to support the common practice of treatment of tick bites with
antibiotics, even in areas known to be endemic for Lyme borreliosis (29,31). In
a study comparing penicillin V and placebo, the risk of acquiring Lyme borrelio-
sis was found to be lower than one would expect, given the infection rate in ticks,
and it was similar to the risk of an adverse reaction to penicillin (30). Patients
should be counseled about the early symptoms of Lyme borreliosis(29).
Recognition and adequate antibiotic treatment of the early stages of Lyme
borreliosis is of paramount importance in preventing Lyme arthritis (31). Ap-
proximately 50% of the patients have the erythema migrans which is a charac-
teristic of Lyme borreliosis. Individuals and doctors should be well aware of this
skin lesion. Prompt antibiotic treatment should be started to prevent the later
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complications of this disease (32). The optimal dose and duration of antibiotic
treatment have not been established for any antibiotic agent (29). Despite
adequate antibiotic treatment, chronic signs and symptoms of Lyme borreliosis
may occur (3). Even in untreated patients, erythema migrans lesions fade within
3 to 4 weeks and other manifestations of the disease may occur only months
later. A relationship with subsequent signs and symptoms may pass unnoticed.
Adequate history taking and showing pictures of erythema migrans can be
helpful in establishing the diagnosis (32). Since only 50 percent of the patients
with Lyme borreliosis have erythema migrans preceding other signs and symp-
toms, a diagnosis of Lyme borreliosis can be difficult to make. Because the
culture or direct visualization of fi. burgdoz/en' from patient specimens is
difficult, serology is currently the only practical laboratory aid for diagnosis.
Antibody titers to fi. bwrgdor/m are present after 4-6 weeks in almost all
patients with Lyme borreliosis. Serologic results, however, should be interpreted
with caution. False positive results and inter and intra laboratory variation have
been reported (33-35). In addition to this problem, there are a large number of
patients with asymptomatic fl. ÖHrgdor/èn infections (36). At present, it is
impossible to differentiate between asymptomatic infections and false positive
serology.
The discriminative value of reporting tick bites as part of the clinical history
is low (32,36). Even the presence of antibodies tofi. öurgdor/en' in the absence
of typical features of Lyme borreliosis such as erythema migrans has a very low
impact on a definite diagnosis of Lyme borreliosis in the normal population (32).
Lyme arthritis has been treated successfully with both oral and parenteral
antibiotics (37,38). The optimal therapy remains to be established. The response
rate to oral doxycycline has been reported to be 72% (38). In cases of persisting
Lyme arthritis other factors such as immunogenetic factors and autoimmunity
may play a role (39,40). The response to antibiotics may occur three months or
longer after completion of the therapy. In all cases of arthritis of unknown origin
the diagnosis of Lyme borreliosis should be considered (41). Progression of joint
damage or other manifestations which occur in the later stages of the disease
may be prevented if appropriate treatment is provided immediately after the
diagnosis of Lyme borreliosis has been established.
SUMMARY
Lyme arthritis may be avoided by preventing tick bites, by recognizing the early
signs and symptoms of Lyme borreliosis, such as erythema migrans, and by
timely antibiotic therapy. Antibiotic treatment of Lyme arthritis may prevent
chronic arthritis.
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How well do general practitioners,
rheumatologists and dermatologists
recognize Lyme borreliosis?
ABSTRACT
/ve: To assess how well early stages of Lyme borreliosis (erythema
migrans and arthritis) are recognized by general practitioners, rheumatologists,
and dermatologists.
i: Cross-sectional study.
: A sample of 51 general practitioners, 23 rheumatologists and 13
dermatologists.
MeasMre/werttt: General practitioners and rheumatologists were tested on 2
cases of Lyme arthritis. General practitioners and dermatologists were tested on
2 cases of erythema migrans shown as photographs. All cases were presented,
among 10 other rheumatological or dermatological cases, using 2 different
formats: open ended questions, prompting for the most likely diagnosis, and
multiple probability estimate questions.
/tesH/w: In the open ended questions, the first case of Lyme arthritis was
correctly diagnosed by 55% of the general practitioners and 96% of the rheuma-
tologists. In the multiple probability estimates, 61% of the general practitioners
and 87% of the rheumatologists rated this case of Lyme borreliosis as highly
probable. The second case of Lyme arthritis was never recognized in the open
ended questions, whereas only 2 general practitioners rated Lyme borreliosis as
highly probable in the multiple probability estimates. The 2 photographs of
erythema migrans were recognized by 16% and 45% of the general practitioners,
and by 92% and 54% of the dermatologists, in the open ended questions. In the
multiple probability estimates, 14% and 14% of the general practitioners and
77% and 46% of the dermatologists rated these 2 cases of erythema migrans as
highly probable.
Cortc/Ms/ons: General practitioners, rheumatologists and dermatologists had
difficulty recognizing early stages of Lyme borreliosis as erythema migrans or
arthritis. Better instruction and education in recognizing the early manifestations
of Lyme borreliosis seems indicated.
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INTRODUCTION
Lyme borreliosis, a tick-borne spirochetal infection, frequently begins with a
characteristic skin lesion, erythema migrans, and is often followed by systemic
manifestations involving the heart, nervous system, or the joints (1). Erythema
migrans is reported in 50-60% of patients. In 15-20% of patients in the United
States, this is followed within several weeks to months by neurological involve-
ment, which may be accompanied by radicular pain, pleocytosis in cerebrospinal
fluid and meningitis, cranial nerve involvement or peripheral neuropathy (2).
Cardiac involvement occurs in 4-8% of patients, most commonly as an atrio-
ventricular block (3). From two weeks to two years (usually six months) after
the onset of the disease, often after intermittent episodes of arthralgia or migra-
tory musculoskeletal pain, nearly 60-80% of patients begin to have brief attacks
of asymmetric, oligoarticular arthritis, primarily in the large joints, and espe-
cially in the knee (4). Chronic arthritis, defined as a year or more of continual
joint inflammation, begins during the second or third year after the onset of the
disease. In severe cases, chronic Lyme arthritis may lead to the erosion of
cartilage and bone and, sometimes, though rarely, to permanent joint disability
(4). Progressive encephalomyelitis has also been described as a severe late stage
of this disease (5). Acrodermatitis chronica atrophicans is a late skin disorder of
the disease, which has been described primarily in Europe (6). In long-standing
cases, chronic joint and bone involvement, including periostitis and subluxations
of the small joints, may be seen underlying the cutaneous lesions.
Recognition and adequate antibiotic treatment of the early stages of Lyme
borreliosis is of paramount importance in preventing the late stages of the
disease (7). One should be aware of the fact that erythema migrans lesions may
fade within 3 to 4 weeks, even in untreated patients, and other manifestations of
the disease, like arthritis may occur only months later. One may be unaware of
the relationship between subsequent signs and symptoms. Lyme borreliosis may
also present itself without proceeding skin lesions, for instance as arthritis of the
knee. Recognition and knowledge of the early dermatologie, especially ery-
thema migrans, cardiac, neurologic, and rheumatic manifestations of the dis-
ease, is important to prevent later stages such as chronic arthritis.
The exact incidence and prevalence of Lyme borreliosis in the Netherlands
are as yet unknown. The estimated incidence is 559 cases of Lyme borreliosis a
year in a population of 15,000,000 (8). Therefore, general practitioners will not
frequently encounter patients with Lyme borreliosis. However, knowledge of
the disease, clinical suspicion and recognition of manifestations, and appropriate
and timely antibiotic treatment, will decrease the burden of illness. At early
stages of the disease (for example erythema migrans) clinical history and
physical examination are the most important tools to detect Lyme borreliosis for
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general practitioners, since antibodies to Borre//a ÖMrgdor/<?n only become
positive after 6 to 8 weeks (9).
Data of the whole spectrum of Lyme borreliosis have only become available
since the first publication by Steere in 1977 (10). The first publications of the
early manifestations of the disease in Dutch literature date from 1987 and 1988
(11-15). The general practitioner may have gained his or her knowledge of Lyme
borreliosis from medical journals rather than from medical textbooks. The
chance that general practitioners have gained experience with Lyme borreliosis
from patients, is estimated as being low, due to the low incidence of the disease.
The present study was performed to answer the following questions: (1) how
well do general practitioners and rheumatologists recognize a typical case
description of Lyme borreliosis, (2) how well do they recognize a later stage of
Lyme borreliosis as arthritis, and (3) how well do general practitioners and
dermatologists recognize erythema migrans.
METHODS
The study was undertaken to assess knowledge of general practitioners about
rheumatic diseases, and was carried out before discussions on a rheumatic
post-graduate training program were started. The ultimate purpose is to install
post- graduate training, which fits the specific needs of the participants. Partici-
pating in the study was supported by the board of the Post-Graduate Education
Committee of the local organization of general practitioners.
General practitioners
In november 1991, a random sample of 58 (73%) of all 79 general practitioners
from Maastricht and the immediate surroundings, was invited to participate in
an evaluation program of knowledge about rheumatic disease. A total of 51
general practitioners agreed to cooperate (a response rate of 88%). Seven refused
to cooperate, mostly due to lack of time. All participating practitioners were
visited in their office by one investigator (AB). The entire evaluation program
lasted 45 minutes for each participant.
Rheumatologists and dermatologists
Twenty-three rheumatologists attending a scientific meeting at the University
Hospital Maastricht in November 1991, agreed to participate. Fourteen rheuma-
tologists worked in private practice and 9 in an academic setting.
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Thirteen dermatologists, 3 from private practice and 10 from an academic
setting cooperated in the study, while attending a meeting of the Dutch Society
of Dermatology in September 1991.
Cases and photographs of skin lesions
Written case descriptions presented to general practitioners and rheumatologists
were: one case each of rheumatoid arthritis, psoriatic arthritis, gout, poly myalgia
rheumatica, pseudogout, systemic lupus erythematodes, ankylosing spondylitis,
reactive arthritis, and two cases of Lyme borreliosis. The first case of Lyme
borreliosis was a classical case with a bite, skin lesion, atrio-ventricular block,
and arthritis. The second case was a patient with recurrent arthritis of the knee
without any other symptoms of Lyme borreliosis (see appendix 1 for detailed
case descriptions).
All ten rheumatologic cases were derived from real patients and compiled by
one of the investigators (AB). Only signs and symptoms of the patients were
given. Results from laboratory tests were not included. A differential diagnosis
for each rheumatic case was composed by one of the investigators (AB) and
three rheumatologists from the Department of Rheumatology of the University
Hospital Maastricht. Each of these four rheumatologists composed a differential
diagnosis for each case description. The eight diagnoses mentioned the most
were used for the definite differential diagnosis used in the study.
Ten colored photographs, (13 x 18-centimeter) of skin lesions, which may
occur in connection with rheumatic diseases, were placed in plastic binders and
presented to the general practitioners and the dermatologists. Skin lesions
presented were: one photograph each of cutaneous lupus erythematodes, ery-
thema nodosum, erythema annulare multiforme, urticaria, vasculitis, drug erup-
tion, and two photographs of psoriasis and erythema migrans. A differential
diagnosis for each case was composed by 2 dermatologists from the Department
of Dermatology of the University Hospital Maastricht in the same way as was
described for the rheumatologists. Regarding the two photographs of erythema
migrans, the clinical diagnosis was confirmed by 2 dermatologists (chapter 1,
figure 1 and 2). Both patients developed erythema migrans within 2 weeks of a
tick bite.
Questions
All rheumatic cases and skin lesions were presented in two formats. The first
was an open-ended question, prompting for the most likely diagnosis. The
second was a so-called multiple probability estimate consisting of several (eight)
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possible diagnoses, for each of which the participant had to rate the probability
on a seven points scale (16). The questions were presented in these two different
formats to assess a possible discrepancy in the answers. The results of the
answers to these two different formats will be touched upon briefly. A thorough
discussion of this subject will be presented elsewhere.
Presentation
The rheumatic cases were presented to the participating general practitioners
and rheumatologists using a computer-interface specially developed for testing
(17). Firstly, all cases were presented linked to the open-ended question. Sec-
ondly, the same cases were presented but were then linked to the multiple
probability estimate. It was not possible to return to a previous screen or correct
answers already given to the open-ended questions, after a participant had seen
the differential diagnosis given in the multiple probability estimate questions.
The answers to all questions were immediately filed in the computer.
The photographs were presented to the general practitioners and dermatolo-
gists by two of the investigators (AB and MR) without any specific comment.
The diagnoses for each photograph were written on separate sheets. The differ-
ential diagnoses for the multiple probability estimate questions were presented
on separate sheets. The participants were not allowed to read back.
Scoring
Since all cases and photographs were derived from real patients, each case
served as its own "gold" standard. Answers to the open-ended questions to both
rheumatic cases and skin lesions were evaluated in two ways: a correct answer
mentioned as a first diagnosis, and listing of the correct answer within the first
three diagnosis. In the multiple probability ratings, rate 6 and 7 were considered
highly probable, rate 3,4, and 5 probable, and rate 1 and 2, highly improbable.
Medical journals
At the end of the test, a list of 17 Dutch and 10 English medical journals of
supposedly easy access to general practitioners was presented. The instruction
for this list was to rate how frequently these journals were read by the general
practitioners on a scale from 1 (never) to 5 (every issue).
The number of published articles about Lyme borreliosis (period 1983-1991)
was known for each journal.
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Computerprogram .
The program used for presentation, data filing, and scoring was written by
Donkers, e/ a/ (17). It consists of an instruction set which allows easy presenta-
tion of a case text, and linking of the text to several (preprogrammed) types of
questions.
Statistics
Counts of correct answers were calculated for each group, variance and means
were compared to each other. Cross-tabulations were made to compare answers
to open-ended questions and probabilities given on the multiple probability
estimates. For categorical data, a X^ test was used to test for significant differ-
ences between groups. A probability value p< 0.05 was considered statistically
significant.
RESULTS
Case 1 (a typical case of Lyme borreliosis with erythema
migrans, bite, atrioventricular block, and arthritis)
Lyme borreliosis as the first diagnosis in the open-ended questions was given by
21, out of the 51 general practitioners (41.2%), compared to 22 out of 23
rheumatologists (95.7%)(p<0.001). Lyme borreliosis listed in the differential
diagnosis (first three diagnoses) occurred in 28 of the general practitioners
(54.9%), compared to 22 of 23 rheumatologists (95.7%) (p<0.001) (Table 1).
The diagnoses mentioned for this case by the general practitioners in the open
ended-questions were rheumatic fever (8 x), reactive arthritis (6 x), septic
arthritis (3 x), endocarditis (3 x), gout (3 x), postinfectious arthritis (3 x), viral
infection (1 x), erysipelas (1 x), and arthritis of unknown etiology (2 x).
In the multiple probability estimate questions, Lyme borreliosis was rated as
highly probable (rate 6 and 7) by 31 of the general practitioners (60.7%), as
probable (rate 3,4, and 5) by 7 (13.7%), and as highly improbable (rate 1 and 2)
by 13 (25.5%) (Table 2).
When the answers to the open-ended questions and the multiple probability
estimates were compared, 54.9% gave the correct answer and 60.8% rated Lyme
borreliosis as highly probable.
Of the 21 general practitioners who diagnosed Lyme borreliosis correctly as
the first diagnosis in the open-ended questions, eighteen rated Lyme borreliosis
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Table 1. Presence of correct answers within the first three diagnoses given to two cases of
Lyme borreliosis and two photographs of erythema migrans (open-ended questions) by
rheumatologists, general practitioners, and dermatologists.
Rheumatologists
N = 23
N %
General Practitioners
N = 51
N %
Dermatologists
N= 13
N %
Case 1
Case 2
Photo 1
Photo 2
22
1
95.7
4.3
28
0
8
23
54.9
0
15.6
45.0
12
7
92.3
53.8
Table 2. Probability ratings in the multiple probability estimate questions to two cases of
Lyme borreliosis presented to general practitioners and rheumatologists.
General practitioners (n=51) Rheumatologists (n=23)
Highly Probable Highly Highly Probable Highly
Probable Improbable Probable Improbable
N % N % N % N % N % N %
Case
Case
1
2
31
2
60.7
3.9
7
4
13
7
.7
.8
13
45
25.5
88.2
20
0
86.9
0
0
4
0
17.4
3
19
13
82.6
in the multiple probability estimate questions as highly probable (rate 6 and 7),
one as probable (rate 5), and two as improbable (rate 1 and 2) (Table 3).
In the multiple probability estimate questions, Lyme borreliosis was rated
highly probable (rate 6 and 7) by 20 rheumatologists (86.9%), and improbable
(rate 1 and 2) by 3 of the rheumatologists (13%) (Table 2). Of the 22 rheuma-
tologists who gave the correct answer in the open-ended questions, nineteen
rated Lyme borreliosis as highly probable (rate 6 and 7), two as probable (rate
5), and one as improbable (rate 2) (Table 3).
106
Table 3. Distribution of probability scores on multiple probability estimate questions among
those participants who correctly diagnosed Lyme borreliosis or erythema migrans as a first
diagnosis in the open-ended questions.
Rheumatologists
General practitioners
Rheumatologists
General practitioners
Dermatologists
General practitioners
Dermatologists
General practitioners
Case 1
Case 1
Case 2
Case 2
Photo 1
Photo 1
Photo 2
Photo 2
N
22
21
0
0
9
6
3
16
Highly
probable
19
18
0
0
9
2
3
6
Probable
2
1
0
0
0
2
0
1
Highly
improbable
1
2
0
0
0
2
0
9
Case 2 (recurrent arthritis of the knee)
None of the general practitioners and rheumatologists mentioned Lyme bor-
reliosis in their diagnosis to the open ended-questions. Only one rheumatologist
mentioned Lyme borreliosis in his differential diagnosis (Table 1). This rheuma-
tologist rated Lyme borreliosis as improbable (rate 2) in the multiple probability
estimate questions.
In the multiple probability estimate questions, Lyme borreliosis was rated as
highly probable (rate 6) by only 2 of the general practitioners (3.9%), as probable
(rate 3,4, and 5) by 4 (7.8%) and as improbable (rate 1 and 2) by 45 of the general
practitioners (88.2%) (Table 2). Lyme borreliosis was rated as highly probable
by none of the rheumatologists, as probable by 4 (17%), and as improbable by
19 of the rheumatologists (82.6%) (Table 2). The first diagnosis given by both
the general practitioners and rheumatologists to this case, in the open-ended
questions, are shown in Table 4.
Erythema migrans (photograph 1)
Six, out of the 51 general practitioners (11.8%) mentioned erythema migrans as
the first diagnosis in the open-ended question to the first photograph compared
to 9, out of 13 dermatologists (69.2%) (p<0.001). Erythema migrans occurred
in the differential diagnosis (first three diagnoses) of the first photograph in 8 of
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Table 4. First diagnosis mentioned by general practitioners and rheumatologists to the case
with recurrent arthritis of the knee in the open-ended questions
Gout
Arthritis of unknown etiology
Reactive arthritis
Rheumatoid arthritis
Ankylosing spondylitis
Gonococcal arthritis
Viral arthritis
Trauma
Osteoarthritis
Locking phenomenon
General practitioners
n=5
n
24
14
2
4
0
3
1
0
2
1
1
%
47.1
27.5
4
7.8
0
5.9
2
0
3.9
2
Rheumatologists
n=23
n
10
2
6
0
4
0
0
1
0
0
%
43.5
8.7
26.1
0
17.4
0
0
4.3
0
0
Table 5. Probability ratings in the multiple probability estimate questions to two photographs
of erythema migrans presented to general practitioners and dermatologists.
General practitioners (n=51) Dermatologists (n=13)
Highly Probable Highly Highly Probable Highly
Probable Improbable Probable Improbable
N % N % N % N % N % N %
Photo
Photo
1
2
7
7
13
13
.7
.7
10
9
19.6
17.6
34
35
66.7
68.6
10
6
76.9
46.2
3
6
23.1
46.2
0
1
0
7.6
the general practitioners (15.6%), compared to 12 of the dermatologists (92.3%)
(p<0.001) (Table 1).
When the multiple probability estimate questions for the first photograph
were assessed, 7 of the general practitioners (13.7%) rated erythema migrans as
highly probable (rate 6 and 7), 10 (19.6%) as probable (rate 3,4, and 5), and 34
(66.7%) as improbable (rate 1 and 2) (Table 5).
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Of the six general practitioners who listed the first photograph as erythema
migrans in the open-ended question, two rated erythema migrans as highly
probable, two as probable, and two as highly improbable in the multiple prob-
ability estimate questions (Table 3).
Ten of the 13 dermatologists (76.9%) rated the first photograph as highly
probable for erythema migrans, 3 (23.1%) as probable and none as improbable,
in the multiple probability estimate questions (Table 5).
All nine dermatologists who listed erythema migrans in the open-ended
questions of the first photograph, rated erythema migrans as highly probable in
the multiple probability estimate questions (Table 3).
Erythema migrans (photograph 2)
Sixteen general practitioners (31.4%) correctly diagnosed the second photo-
graph as erythema migrans, compared to 3 of the dermatologists (23.1%) (NS).
Twenty-three general practitioners (45%) listed Lyme borreliosis in the differ-
ential diagnosis to the second photograph, and 7 of the dermatologists (53.8%)
(NS) (Table 1).
The second photograph of erythema migrans was rated as highly probable by
7 of the general practitioners (13.7%), as probable by 9 (17.6%), and as
improbable by 35 (68.6%) (Table 5).
Of the sixteen general practitioners who listed erythema migrans in the
open-ended questions of the second photograph, six rated erythema migrans as
highly probable, one as probable, and 9 as highly improbable (Table 3).
The second photograph of erythema migrans was rated as highly probable for
erythema migrans by 6 dermatologists (46.2%), as probable by 6 (46.2%), and
as improbable by one (7.6%) (Table 5).
All three dermatologists who listed erythema migrans in the open-ended
questions of the second photograph, also rated erythema migrans as highly
probable in the multiple probability estimate questions (Table 3).
Four (7.8%) general practitioners suggested erythema migrans as a diagnosis
to the open-ended question, when a photograph of erythema nodosum was
shown, and six (11.7%) when a photograph of erythema annulare multiforme
was shown. Ten dermatologists (76.9%) listed erythema migrans in the open-
ended question, when a picture of erythema annulare was shown.
A variety of diagnoses was suggested as a first diagnosis by general practi-
tioners and dermatologists in the open-ended questions to both photographs of
erythema migrans. Diagnoses mentioned most were: contact allergy (6 x),
mycosis (4 x), discoid lupus erythematodes (4 x), erythema annulare centrifu-
gum (2 x), epizoonosis (27 x). All other diagnoses were mentioned only once.
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; Cases of Lyme borreliosis and erythema migrans
Twenty-eight general practitioners (54.9%) suggested Lyme borreliosis in their
differential diagnosis (first three diagnoses) to case 1. Only three of these
twenty-eight, correctly diagnosed both photographs of erythema migrans. Six
diagnosed photograph 1, and thirteen photograph 2.
Two general practitioners correctly diagnosed both photographs of erythema
migrans, however they did not recognize case 1. Two general practitioners
recognized photograph 1, but did not recognize case 1. Seven general practi-
tioners recognized photograph 2, but did not recognize case 1 as Lyme borrelio-
sis. As stated before, none of the general practitioners recognized case 2 as Lyme
borreliosis.
Medical journals
Eight Dutch medical journals were read regularly by more than 50% of the
general practitioners. Articles about Lyme borreliosis appeared in five of these
eight journals in 1987 to 1991 (11-15,18-32). One journal published an article
about Lyme borreliosis, which included photograph 1 of erythema migrans just
one month before the study was started (8). The other journals were read by less
than 12% of the general practitioners.
DISCUSSION
By assessing knowledge of rheumatic diseases of general practitioners, we
evaluated the recognition and knowledge of Lyme borreliosis among general
practitioners, rheumatologists and dermatologists.
A typical case of Lyme borreliosis with almost all clinical features of the
disease, was easily recognized by most rheumatologists. However, a case of
Lyme borreliosis with recurrent arthritis of the knee, without other preceding
signs and symptoms, was not diagnosed either by rheumatologists or by general
practitioners. Recurrent arthritis attacks, especially of the knee, are a common
feature of Lyme borreliosis and should be recognized by rheumatologist at all
events (4,33).
Most of the general practitioners did not recognize the photographs of ery-
thema migrans. On the other hand, the second photograph of erythema migrans
was only recognized by 54% of the dermatologists. When patients with ery-
thema migrans are not recognized as having Lyme borreliosis, they will prob-
ably not be treated with appropriate antibiotics. This will then increase the risk
of the development of later stages of Lyme borreliosis. Despite the fact several
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papers about Lyme borreliosis have been published in the Dutch literature and
also in journals commonly read by general practitioners, it is clear more infor-
mation about the manifestations of erythema migrans should be given to both
general practitioners and dermatologists. Most of these articles focus on the
entire spectrum of the disease.
The presentation of the questions (open-ended or with a differential diagno-
sis) had a varying influence on the answers of the general practitioners, rheuma-
tologists and dermatologists to the two cases of Lyme borreliosis and the two
photographs of erythema migrans. Some diversity was noticed in the answers
accompanying the two different assessment methods.
We presented the cases of Lyme borreliosis as written cases, primarily for
practical reasons. A possible criticism of this method is, that hypothetical case
scenarios may include selected aspects of clinical reality while neglecting
others, and that physicians may not respond in the same way to hypothetical
scenarios as they do to real ones. We tried to avoid this criticism by deriving our
cases from real patients. A study by Rethans and van Boven suggested no
significant difference in overall score for written case simulations and the use of
standardized real patients (34). Moreover, correlations between written and
performance-based tests appear to be sizable (35). Nevertheless, whenever
possible, it would be interesting to use standardized (simulated) patients with
different stages of Lyme borreliosis to evaluate the real performance of general
practitioners, rheumatologists and dermatologists.
Regarding the photographs of erythema migrans, observing a patient's cu-
taneous problem directly and providing a possibility to ask for accompanying
symptoms and to palpate the skin lesion, is of course a better assessment
procedure. We presented the photographs of erythema migrans without any
comment, because about half the patients with erythema migrans do not remem-
ber a tick bite and sometimes only notice their skin lesion by accident. Fre-
quently, there are no additional supportive data from the clinical history.
For the purpose of gathering knowledge for later use, physicians consistently
report that reading, primarily of medical journals, is their predominant source of
information (36). Since articles about Lyme borreliosis were published in the
majority of journals commonly read by general practitioners, lack of direct
knowledge and low suspicion is probably due to the low chance of encountering
a patient with this disease. We did not inquire about journals read by rheumatol-
ogists and dermatologists.
In summary, better education aimed at recognition of the (early) manifesta-
tions of Lyme borreliosis is necessary for general practitioners, rheumatologists,
and dermatologists to limit morbidity due to late stages of Lyme borreliosis.
I l l
The enthusiastic cooperation of the general practitioners, rheumatologists, and
dermatologists to participate in the "evaluation rheumatic knowledge study" is
greatly appreciated.
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APPENDIX 1
Case 1
A 35 year old, male nurse from a wooded area, visits your practice complaining
about a warm, swollen right knee he has had for a couple of days. In fact he
already complained about his knee during a short stay in the coronary care unit.
He was admitted because of acute dizziness. The diagnosis was second degree
atrio-ventricular block, which came in to remission spontaneously. You pre-
scribed him some acetaminophen some weeks before this admission, because of
flu-like complaints with slight fever, chills and lymphadenopathy. He remem-
bered some sort of bite with redness on his right leg, which had been visible
during a couple of weeks after this bite.
At physical examination, there is a warm, heavily swollen knee with severe
limitation of movements.
Open-ended question: what is (are) your most likely diagnoses?
Multiple probability estimate question: rate the probability of each of the
following diagnoses on a scale from 1 (highly improbable to 7 (highly probable):
• Viral arthritis
• Rheumatic fever
• Reactive arthritis
• Gout
• Lyme borreliosis
• Septic arthritis
• Systemic Lupus Erythematodes
• Rheumatoid arthritis
Case 2
A 47 year old pilot, visits your practice complaining about a warm, swollen left
knee, which has lasted several weeks already. He does not complain about any
pain. Flexion is severely limited. He has used some NSAID's without any result.
Last year he had the same problem. The arthritis lasted for 8 weeks. Due to
his job, he travels around the whole world. After long-distance flights, he has
some lower back pain. He takes a drink now and then to fall asleep.
Open-ended question: What is (are) your most likely diagnoses?
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Multiple probability estimate question: rate the probability of each of the
following diagnoses on a scale from 1 (highly improbable) to 7 (highly prob-
able):
• Rheumatoid arthritis
• Reiter's syndrome
• Gout
• Spondylitis ankylopoetica
• Lyme borreliosis
• Osteoarthritis
• Meniscal tear
• Gonococcal arthritis
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General discussion.
Lyme borreliosis
Differences in the prevalence of rheumatic manifestations of Lyme borreliosis
have been reported between various countries, especially between the United
States and Europe. Arthritis is said to be a common manifestation of the disease
in the United States, Germany, Switzerland and Belgium (1-4). Other studies
also from Europe, have reported considerably lower prevalence of rheumatic
manifestations of Lyme borreliosis (5-10).
Several reasons have been proposed for these differences. (1) A diversity
between American and European isolates of fiorre//a ourgcfor/i?/-/ (B. öurg-
c/or/?rO has been pointed out (11). (2) The definition of Lyme disease in the
United States results from the identification of patients with arthritis or erythema
migrans only, leading to probable overreporting of rheumatic manifestations. (3)
Early (versus late or no) treatment of erythema migrans which is supposed to be
common in Europe, could have prevented the development of arthritis (12). (4)
A lack of diagnostic awareness of Lyme borreliosis or its rheumatic manifesta-
tions, and the impression that Lyme disease is a rare disease in Europe could also
be responsible for the reported differences (13,14). (5) Patients with Lyme
borreliosis are seen by different medical specialists like general practitioners,
dermatologists, neurologists, and rheumatologists. Each of these specialists will
focus on their own specialty, and there is a possibility that other Lyme symptoms
will be overlooked.
The clinical features of the reported Dutch patients with Lyme borreliosis,
closely resemble the description of the disease reported from the United States.
However, the majority of the Dutch patients presented with arthritis to rheuma-
tologists. The possibility of bias in the direction of arthritis can not be precluded.
At this time, it is impossible to say whether there are real differences between
the United States and Europe in the incidence of rheumatic manifestations of
Lyme borreliosis. We have the feeling that a lack of awareness is responsible for
most of the reported differences in the rheumatic manifestations of the disease.
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The exact incidence and prevalence of Lyme borreliosis in the Netherlands is
unknown. The estimated incidence is 560 cases a year. Lyme arthritis usually
responds to antibiotic treatment. Although not a frequent cause of arthritis, early
diagnosis may significantly reduce the burden of illness due to this disease and
may prevent long-lasting disability. Lyme borreliosis should be considered in
the differential diagnosis of patients with arthritis.
Pitfalls of antibody testing
Serologic testing for diagnostic confirmation is used when a pathogen cannot be
easily cultivated or observed. This is a less desirable method, but it is essentially
the only choice now available for laboratory support of Lyme borreliosis. The
predictive accuracy of a positive or negative serologic result depends on the
pre-test likelihood of Lyme disease being present. The serologic test should not
be requested indiscriminately; it should be ordered solely to confirm a diagnosis
based on epidemiological and clinical evidence (15-17).
There is a risk that the test will be falsely negative if serum is obtained too
early in the infection, since antibodies only become positive after 3 to 6 weeks.
Erythema migrans needs no serologic confirmation before antibiotic treatment
is started.
There is also a risk of false positivity. The illnesses known to be associated
with false positive serology results include infectious mononucleosis, rheuma-
toid arthritis, systemic lupus erythematodes, and other spirochetal diseases such
as periodontal disease (18). It remains to be determined whether Western blot
analysis can discriminate between false positivity and true positivity.
In addition, a large number of people have asymptomatic fl. öurgdor/m
infections. For instance, positive Lyme serology is common in Swiss orienteers,
but the disease itself occurs infrequently (15). The same results have been found
in our study described in chapter 5 of this thesis. It is therefore necessary, to
carefully evaluate the clinical signs and symptoms of patients who are suspected
to have Lyme disease. Complaints present should be attributable to Lyme
disease (19). In countries with a low prevalence of Lyme disease, such as
Switzerland and the Netherlands, and a high prevalence of asymptomatic posi-
tive serology, diagnostic testing is of limited value as was easily shown by
application of likelihood ratios for antibodies to fl. burgdor/i?n in chapter 5.
Another major point of concern is the quality of serologic testing (20-24). The
lack of a national reference collection or other common source of serum
specimens, antigens, and other reagents forces laboratories to establish their own
standards. All tests should meet acceptable performance standards, and there
should be intra-laboratory standardization and reproduction of results. The
clinician should demand information from the laboratory about their inter and
118
intra-test accuracy, sensitivity, and specificity. In the absence of a reference
standard, we compared our results of testing with sera from the laboratory of the
Department of Zoology, University of Neuchatel, Switzerland (Head Prof. A
Aeschlimann). There was good agreement between laboratories (r=0.68; p
0.001). With our methods, the sensitivity of the serologic tests varied from 40%
to 96% depending on the clinical manifestations in cases of definite Lyme
disease: early Lyme borreliosis, 40% (n=25); and late Lyme borreliosis, 96%
(n=27) (unpublished results). Evaluation of commercial kits and controlled
proficiency testing of diagnostic laboratories are badly needed.
Likelihood ratios
Application of likelihood ratios in the clinical situation can be an easy way to
decide whether a diagnostic test may be of any help in supporting a diagnosis.
Likelihood ratios need not change with changes in the prevalence (or pretest
probability) of the target disorder (25). The pretest or prevalence of disease,
however, has a strong influence on the usefulness of a test as was demonstrated
in our studies described in chapter 5 and 6. Prevalence of disease should be
known before likelihood ratios can be applied. The prevalence of disease in the
individual patient can usually be estimated based on experience or literature.
Diagnostic tests discriminate best when the pretest probability is about 40-
60%. When the pretest probability of Lyme borreliosis is as low as 0.1 % (normal
Dutch population), one should try to increase the pretest probability by sub-
sequent application of likelihood ratios for known symptoms and signs, and
possible laboratory tests. We believe that the likelihood ratios provided in this
thesis for recognition of photographs of erythema migrans, tick bites, antibodies
to fi. bwrgdor/èn, and different levels of the clinical history of patients with
arthritis of undetermined etiology, can be helpful in making a diagnosis of Lyme
borreliosis, if a certain degree of dependency is taken into account (25).
Education
In chapter 8, we conclude that better education is needed about the early
manifestations of Lyme borreliosis for general practitioners, as well as for
dermatologists and rheumatologists. If one is unaware of the diagnosis Lyme
disease, one will probably not treat patients with appropriate antibiotics, and
subsequent later stages of the disease are likely to occur. For instance, arthritis
will probably be treated with non-steroidal anti-inflammatory drugs. The
general practitioner plays the most crucial role in diagnosing patients with Lyme
borreliosis. Publications about the disease have been published in journals
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reported to be read by general practitioners. Lack of knowledge is probably due
to the low chance of encountering a patient with this disease. Registration of all
patients diagnosed as having Lyme disease, could give information about the
true incidence and prevalence of Lyme disease in the Netherlands. This is
probably the only way to embrace the entire problem of Lyme borreliosis in our
country. Based on this information, strategies for better instruction and educa-
tion can be developed.
Diagnosis
Lyme disease is typically defined by clinical evidence and serologic results
should only be used to support a clinical diagnosis. Seropositivity for antibodies
to fi. öurgdor/è/v does not ensure the current clinical problem is due to Lyme
borreliosis. Complaints, symptoms and signs should be related to manifestations
described in patients with Lyme borreliosis, especially in reports about the
natural history of untreated Lyme patients (1,26). Since there is no real "gold"
standard, clinical evidence should outweigh serologic results. Patients with
Lyme arthritis usually remain seropositive for antibodies to fi. owrgrfoz/m after
appropriate antibiotic treatment. Vague or mild to moderate symptoms and
fatigue may incorrectly suggest persistence of infection, leading to further
antibiotic therapy (27). Unnecessarily prolonged antibiotic therapy of pre-
viously treated Lyme disease for these kinds of symptoms should be avoided.
On the other hand, recurrent courses with antibiotics for Lyme arthritis may be
necessary.
In chapter 6, we have tried to indicate in which patients with arthritis a
diagnosis of Lyme borreliosis can be expected and for which patients with
arthritis, requests for serology can be of any help. Exclusion of other causes for
arthritis is essential. However, it is still possible that patients with arthritis
without any other features of Lyme borreliosis, and positive antibodies to fi.
öwrgdor/m, in fact may be asymptomatic, and that their arthritis is due to
another cause. A follow-up study of these patients would be necessary. If the
clinical presentation of the arthritis suggests Lyme arthritis, like for instance
recurrent arthritis of the knee, the diagnosis of Lyme arthritis should be con-
sidered. However, if the arthritis is located in joints not easily affected by fl.
bwrgdor/ieri, other causes for the arthritis should be considered. Currently,
however, in case of doubt, these patients will probably be treated with antibiotic
therapy. As long as we have no definite "gold" standard, physicians may be
advised to prescribe antibiotic treatment for patients with arthritis and positive
serology for fl. ÖM/-grfor/«n' to prevent development of later stages of Lyme
borreliosis.
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In summary
Lyme borreliosis is a clinical diagnosis, and serologic tests should only be used
to support a high clinical suspicion.
The clinical features of the Dutch patients with Lyme arthritis closely re-
semble the descriptions of the disease reported from the Unites States. Reported
differences are probably due to a lack of awareness.
Although not a frequent diagnosis, Lyme arthritis should be considered in the
diagnosis of patients with arthritis, since antibiotic treatment is usually effective
and may reduce the burden of illness and development of later stages of this
disease.
There is no evidence that fi. öurgdor/en is associated with ankylosing spon-
dylitis.
Asymptomatic seropositivity for antibodies to #. ft«rgdo//m does frequently
occur. These patients do not require antibiotic treatment. The clinical history is
a more powerful diagnostic tool than Lyme serology. Recognition of erythema
migrans has more impact on the diagnosis of Lyme borreliosis than simply
testing for antibodies to B. öurgtfor/è/v.
Likelihood ratios can be a contributing factor in deciding to request antibodies
to fi.6«rg<ior/i?/7 in patients with arthritis of undetermined etiology.
Lyme arthritis may be avoided by preventing tick bites, by recognition of the
early symptoms and signs of Lyme borreliosis, such as erythema migrans, and
by timely antibiotic treatment.
Better instruction and education about the early manifestations of Lyme
borreliosis is necessary for general practitioners, dermatologists, and rheumatol-
ogists to prevent later stages of Lyme borreliosis.
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Summary
This thesis deals with several steps of the Technology Assessment Iterative
Loop as applied to Lyme borreliosis.
Chapter 1 gives an overview of the entire spectrum of Lyme borreliosis. The
causative agent, the spirochete fiorre/j'a èürgdor/èn (fi. ÖMrgdor/èn), and vec-
tor, foodes na/uw ticks, are briefly discussed. Clinical manifestations are de-
scribed, but, the chapter focuses on Lyme arthritis in particular. A summary is
given of the diagnostic tests currently used, and of the antibiotic treatment
recommended up to the present.
In chapter 2, the results of a survey among all 118 Dutch rheumatologists are
described (response rate 85%). The survey was conducted to investigate how
frequently cases of Lyme borreliosis were diagnosed among Dutch rheumatol-
ogists, to determine whether there are striking differences in the clinical pattern
of Lyme arthritis between the United States and Europe, and to assess the
prevalence of HLA-DR antigens among Dutch patients with Lyme arthritis. The
survey yielded 42 patients with Lyme arthritis. The arthritis was non-persisting
in all these patients. A tick bite was reported by 23 of the patients (55%).
Erythema migrans was recalled by 19 patients (45%). Cardiac manifestations
occurred in 4 patients (9%), and neurologic symptoms in 14 patients (33%).
Using ELISA or IFA technique 37 patients (88%) were found to have positive
antibodies to B. b«rg<ior/<?n. The distribution of HLA-DR alleles of 28 of these
patients was not different from the normal population. It was concluded that the
clinical features of the Dutch patients with Lyme arthritis closely resemble the
description of the disease reported from the United States.
In chapter 3, 73 patients with arthritis of undetermined etiology from the
outpatient departments of rheumatology situated in the most southern part of the
Netherlands, were studied by questionnaire and interviewed for clinical mani-
festations suggestive of Lyme borreliosis, together with patients who had other-
wise classified arthritis and healthy controls. The prevalence of antibodies to fi.
ö«rgrfo//(?n' was determined in these three groups. A definite diagnosis of Lyme
borreliosis could be made in only one patient, who belonged to the arthritis of
undetermined etiology group. This patient had erythema migrans, arthritis of the
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knee, and positive antibodies to fl. burgc/or/èn'. Nine patients (3 from the
arthritis of undetermined etiology group, 2 from the classified arthritis group,
and 4 from the healthy controls) had positive antibodies to 5 . bwrgdoz/m'
without any other clinical symptoms of Lyme disease. They were not considered
to have Lyme disease.
The presence of clinical manifestations of Lyme borreliosis and the preva-
lence of IgG antibodies to fl. ÖMrgdor/en, were assessed among 125 patients
with ankylosing spondylitis from the outpatient departments of rheumatology of
the University Hospital of Leiden, the Medisch Spectrum Alkmaar, and the
Gemini-Hospital of Den Helder (chapter 4) to study the relationship between
fl. ö«rgrfor/eW and spondylarthropathy. Several pictures of erythema migrans
were shown to all participants. A standardized questionnaire assessing tick bites,
cardiac, neurological, and musculoskeletal manifestations was completed. None
of the ankylosing spondylitis patients had clinical features of Lyme borreliosis.
IgG antibodies to B. OMrgdor/en were present in 11 of 125 patients (8.8%).
There was no difference regarding positive antibodies tofi. bwrgdor/er/ between
HLA-B27 positive and HLA-B27 negative patients. The results were compared
to age-matched controls. The percentage of positive antibodies (20%) in the
control group was even higher than in the ankylosing spondylitis patients.
However, this percentage of seropositivity is quite comparable to the findings in
a group of blood donors from the same geographic area (17%). This study does
not provide evidence that fl. ÖM/g<io//<?n is associated with ankylosing spondyl-
itis as has been suggested before for reactive arthritis.
In chapter 5, the history of clinical Lyme borreliosis and the prevalence of
positive antibodies to fi. bwrg<ior/<?n were studied in 431 Dutch hunters. Four
pictures of erythema migrans in different stages were shown to all participating
hunters. They were also asked to complete a questionnaire, which dealt with
exposure to ticks and possible manifestations of Lyme borreliosis. The presence
of antibodies to fi. bwrgdor/m was determined in all participants. After six
months, a follow-up study was performed among the hunters with a probable or
definite diagnosis of Lyme borreliosis, with positive serology and hunters with
ambiguous symptoms. The purpose of this follow-up study was to detect a
delayed increase of the optical density value of serum in hunters with ambiguous
symptoms, and to evaluate development of possible clinical Lyme manifesta-
tions in hunters with positive serology, who did not have any symptoms in the
first study. The majority of the hunters (336 or 78%) did not report any
complaints, had not suffered from erythema migrans as shown on the pictures
provided them, and had no positive antibodies to fi. öwrgdor/en. Four hunters
had definite Lyme borreliosis; three hunters had erythema migrans without
antibodies to fi. bw/-gcfor/<?n and one had arthritis with positive antibodies.
Sixty-five of the 431 hunters did not have any complaints, but had positive
antibodies to fi. burgdor/en. This means that
 15.1% of the hunters were asymp-
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tomatic seropositive. The 6 month follow-up study among 95 eligible hunters
had a response of 69.5%. It did not reveal any new cases of Lyme borreliosis.
Data from this study and the studies described in chapter 3 and 4, were pooled
to calculate likelihood ratios for the recognition of erythema migrans, the
recognition of tick bites, and the presence of antibodies to B. öurgdoz/m. The
likelihood ratio for recognition of erythema migrans is 21.3; for tick bites, 3.6,
and for the presence of antibodies to B. bwrgrfor/en, 3.5. These likelihood ratios
were applied in a nomogram adapted from Fagan for the normal population and
a population at risk to strengthen the influence of the pretest probability on the
usefulness of a test. In a normal population, which has a low pretest probability
of about 0.1%, a considerable posttest probability of Lyme borreliosis can only
be reached when the presence of the three variables is applied sequentially. In a
population with a higher pretest probability such as Dutch hunters (2%), the
posttest probability was considerably higher; recognition of erythema migrans
yields a posttest probability of as high as 30%. When the three variables are
combined, the posttest probability is nearly 75%. It was concluded that the
clinical history of a patient is a more powerful diagnostic tool than Lyme
serology. Lyme serology should not be used in any form of screening for Lyme
disease.
Chapter 6 describes a study in which clinical data of 102 patients with
arthritis of undetermined etiology were analyzed to investigate whether the
presence of positive antibodies to B. bwrgdor/en could be predicted, in order to
improve the appropriateness and efficiency of diagnostic serologic tests and
subsequent antibiotic treatment. The clinical data were blindly ranked from 1 to
4(1: Lyme arthritis unlikely, and 4: Lyme arthritis very likely). Antibodies to B.
ÖMrgdor/en were positive in 9 out of 102 patients (9%). Six, out of fifteen
patients with rank 3 and 4, had positive antibodies (40%), in contrast to only 3,
out of 87 patients, with rank number 1 and 2 (4%). The likelihood ratio of
positive Lyme serology for patients ranked 3 and 4 was 12.0, for patients ranked
2 to 4,4.5, and for patients with arthritis of the knee, 3.0. These likelihood ratios
were associated with a posttest probability of 55%, 30%, and 20% respectively.
The conclusions from this study are that the clinical history in patients with
arthritis of undetermined etiology can largely predict the presence of antibodies
to B. ÖHrgcfor/en, and that the likelihood ratio can be a contributing factor in
deciding to request antibodies to B. öwrgrfor/en in this group of patients.
Chapter 7 gives a brief overview of how to prevent Lyme borreliosis and
especially Lyme arthritis. Reducing the incidence of tick bites is one of the first
goals to attempt in preventing Lyme arthritis. Control methods are briefly
discussed. Recognition and adequate antibiotic treatment of the early stages of
Lyme borreliosis is of paramount importance in preventing Lyme arthritis.
General practitioners, rheumatologists, and dermatologists play a crucial role in
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preventing Lyme disease, since they are probably among the physicians who
first encounter patients with tick bites, erythema migrans, and arthritis.
The results of a study, in which the recognition and knowledge of Lyme
borreliosis among general practitioners, rheumatologists, and dermatologists are
evaluated, are described in chapter 8. Two cases of Lyme borreliosis, and two
colored pictures of erythema migrans were presented to 51 general practitioners,
23 rheumatologists, and 13 dermatologists. Although several papers have been
published in the Dutch literature about Lyme borreliosis, only 16% of the
general practitioners recognized the first photograph of erythema migrans com-
pared to 92% of the dermatologists. The second photograph of erythema mi-
grans was recognized by 45% of the general practitioners, and only by 54% of
the dermatologists. One case of Lyme borreliosis was diagnosed by 55% of the
general practitioners and 96% of the rheumatologists. The other case of Lyme
arthritis was not recognized at all, neither by general practitioners nor by
rheumatologists. It was concluded that better instruction and education about the
early manifestations of Lyme borreliosis is necessary for general practitioners,
rheumatologists, and dermatologists to prevent morbidity due to later stages of
Lyme borreliosis.
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Samenvatting
In dit proefschrift worden verschillende stappen van de Technology Assessment
Iterative Loop besproken, toegepast op Lyme borreliosis.
Lyme borreliosis is een systeem ziekte met voornamelijk afwijkingen in de
huid, het centraal en perifeer zenuwstelsel, het hart, de spieren en gewrichten.
De ziekte wordt veroorzaakt door de spirocheet Borre/ia &Mrgdor/en' (fi.
die wordt overgebracht door de beet van een teek, in Nederland
In Hoofdstuk 1 wordt een overzicht gegeven van de ontdekking van de
ziekte, de vector, de spirocheet, de klinische symptomen, de methoden om de
ziekte te diagnostiseren en de tot nu toe gebruikte therapie.
Hoofdstuk 2, laat de resultaten zien van een enquête gehouden onder alle
Nederlands reumatologen. Deze enquête werd gehouden om te onderzoeken
hoe vaak de diagnose Lyme borreliosis werd gesteld, of er verschillen zijn
tussen de klinische verschijnselen van Nederlandse patiënten en de voorname-
lijk in de Amerikaanse literatuur beschreven patiënten en om de HLA typering
van de Nederlandse patiënten te bepalen. De enquête bracht 42 patiënten aan het
licht met gewrichtsontstekingen ten gevolge van Lyme borreliosis. Erythema
migrans ging bij 19 (45%) patiënten vooraf aan de artritis. Drie en twintig
patiënten (55%) konden zich een teek beet herinneren. Cardiale verschijnselen
kwamen voor bij 4 patiënten (9%) en neurologische klachten bij 14 patiënten
(33%). Zeven en dertig patiënten (88%) hadden positieve antistoffen tegen fl.
ÖMrgdor/m. De HLA typering van 28 Lyme artritis patiënten was niet verschil-
lend van de Nederlandse bevolking. De klinische symptomen van de Nederland-
se Lyme patiënten lijken overeen te komen met de in de literatuur beschreven
patiënten.
Hoofdstuk 3 beschrijft het resultaat van een studie onder 73 patiënten met
artritis van onbekende oorsprong afkomstig van de 3 zuid Limburgse reumato-
logie poliklinieken. Deze patiënten werden geïnterviewd over mogelijke symp-
tomen passend bij Lyme borreliosis. Twee controle groepen bestaande uit
patiënten met een geclassificeerde artritis en een groep gezonde personen
werden eveneens geïnterviewd. Bij al deze personen werden antistoffen tegen
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B. ÖMrgrfor/m bepaald. Slechts één patiënt bleek te lijden aan Lyme borreliosis.
Hij had een erythema migrans voorafgaand aan een artritis van zijn knie. Zijn
antistoffen waren positief. Negen patiënten (3 uit de groep van artritis met
onbekende origine, 2 uit de groep met geclassificeerde artritis en 4 uit de
gezonde personen groep) hadden positieve antistoffen tegen B. öurgJor/ên
zonder klinische verschijnselen van Lyme borreliosis. Zij worden beschouwd
als asymptomatisch seropositief.
De mogelijke klinische manifestaties van Lyme borreliosis en de aanwezig-
heid van antistoffen tegen B. ÖMz-gdor/m werden onderzocht bij 125 patiënten
met spondylitis ankylopoetica uit Leiden, Alkmaar en den Helder (Hoofdstuk
4). Bij geen van deze patiënten kon de diagnose Lyme borreliosis worden
gesteld. Wel hadden 11 van deze 125 patiënten positieve antistoffen tegen B.
bwrgdor/en. Er was geen verschil tussen HLA B27 positieve en HLA B27
negatieve patiënten. In vergelijking met een naar leeftijd vergelijkbare groep
controle personen was het aantal patiënten met antistoffen tegen B. öwrgdor/èn
zelfs lager. B. Zjurgdor/èn lijkt derhalve niet te kunnen worden toegevoegd aan
de lijst met mogelijke verwekkers voor spondylitis ankylopoetica.
Het voorkomen van Lyme borreliosis werd ook onderzocht in een groep
personen die een hoger risico op deze ziekte hebben dan de algemene bevolking
(Hoofdstuk 5). Nederlandse jagers werden geïnterviewd aan de hand van een
gestandaardiseerde lijst met vragen zoals ook gebruikt voor de patiënten met
artritis van onbekende oorsprong en de spondylitis ankylopoetica patiënten. Bij
alle deelnemers werden antistoffen tegen B. èurgdor/ien bepaald. Na 6 maanden
werden 95 jagers met mogelijke Lyme borreliosis, dubieuze symptomen en
positieve serologie, uitgenodigd voor een vervolg studie. De meerderheid van
de jagers (336, 78%) bleek geen enkele klacht passend bij Lyme borreliosis te
hebben en had ook geen positieve antistoffen. Vier jagers (0.9%) bleken Lyme
borreliosis te hebben, 3 met erythema migrans zonder positieve antistoffen en
één met een artritis en positieve antistoffen. Opvallend was dat 65 jagers
(15.1%) antistoffen tegen B. bMrg<ior/<?n hadden zonder enig klinisch symp-
toom van deze ziekte. De vervolg studie liet geen nieuwe gevallen zien van
Lyme borreliosis.
De gegevens van de studies beschreven in hoofdstuk 3, 4 en 5, werden
samengevoegd om likelihood ratio's te berekenen voor het herkennen van foto's
met erythema migrans, teek beten en de aanwezigheid van antistoffen tegen B.
burgdor/eri. De likelihood ratio voor het herkennen van foto's van erythema
migrans is 21.3; voor teek beten, 3.6, en voor de aanwezigheid van antistoffen
tegen B. burgdoz/en, 3.5. Deze likelihood ratio's werden toegepast in een
nomogram volgens Fagan zowel voor de normale Nederlandse bevolking als
voor een risico groep. Voor de Nederlandse bevolking wordt pas een aanzienlij-
ke post-test waarschijnlijkheid behaald als deze 3 likelihood ratio's achter
elkaar toegepast worden. In een bevolkingsgroep met een hogere pre-test waar-
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schijnlijkheid zoals jagers, is de post-test waarschijnlijkheid hoger; herkenning
van foto's met erythema migrans geeft een post-test waarschijnlijkheid van
30%. Als de drie mogelijkheden worden gecombineerd is de post-test waar-
schijnlijkheid bijna 75%. De anamnese van een patiënt is derhalve belangrijker
dan het testen op de aanwezigheid van antistoffen tegen fl. bwrgdfor/i?/-/.
Om te onderzoeken of de aanwezigheid van antistoffen tegen fl. öwrgdor/èn
bij patiënten met artritis van onbekende oorsprong voorspeld kon worden op
grond van de anamnese en het lichamelijk onderzoek, werden de klinische
gegevens van 102 Leidse patiënten onderzocht (Hoofdstuk 6). Alle patiënten
kregen een rangnummer van 1 tot 4, op basis van de klinische gegevens:
rangnummer 1 betekende geen aanwijzingen voor Lyme borreliosis en rang-
nummer 4, duidelijk aanwijzingen voor Lyme borreliosis. Negen van de 102
patiënten (9%) bleken antistoffen te hebben. Van de patiënten met rangnummer
3 en 4 hadden 6 patiënten (40%) positieve antistoffen in tegenstelling tot 3 van
de 87 patiënten (4%) met rangnummer 1 en 2. De likelihood ratio voor rang-
nummer 3 en 4 is 12.0; voor patiënten met rangnummer 1 en 2, 4.5. Voor
patiënten met een artritis van de knie is de likelihood ratio 3.0. De hiermee
corresponderende post-test waarschijnlijkheden zijn 55%, 30% en 20%. Ook uit
deze studie blijkt dat de anamnese en het lichamelijk onderzoek de belangrijkste
factoren zijn voor het stellen van de diagnose Lyme borreliosis.
Hoofdstuk 7 geeft een kort overzicht van de manieren om Lyme borreliosis
en vooral artritis ten gevolge van deze ziekte te voorkomen. Het herkennen van
de vroege verschijnselen van Lyme borreliosis zoals erythema migrans en de
artritis aanvallen en het op tijd behandelen van deze verschijnselen is zeer
belangrijk om latere stadia van de ziekte te voorkomen. Hierbij is de rol van
huisartsen, dermatologen en reumatologen zeer belangrijk omdat zij de patiën-
ten in een vroeg stadium van de ziekte zullen zien.
De kennis van huisartsen, dermatologen en reumatologen op het gebied van
Lyme borreliosis kon worden getest aan de hand van 2 foto's van erythema
migrans en 2 gevallen van patiënten met Lyme borreliosis (Hoofdstuk 8).
Slechts 16% van de onderzochte huisartsen herkende de eerste foto van erythe-
ma migrans en 45% de tweede foto. De dermatologen echter herkenden de
eerste foto in 92% en de tweede foto slechts in 54%. Het eerste geval met Lyme
borreliosis werd herkend door 55% van de huisartsen en door 96% van de
reumatologen. Het tweede geval van Lyme borreliosis, een patiënt met recidi-
verende artritis van de knie, werd door huisartsen, noch door reumatologen
herkend. Betere instructie en voorlichting over de verschijnselen van Lyme
borreliosis lijkt derhalve aangewezen om de latere gevolgen van de ziekte te
voorkomen.
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